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 Texas House Bill 790 resulted in the expansion of the newborn screening panel 
from 7 to 27 disorders. The long-term economic implications of this expansion have not 
been studied.  The objective of this study was to estimate the incremental cost-
effectiveness of the expanded newborn screening program compared to the previous 
standard screening in Texas.   
A Markov model (for a hypothetical cohort of Texas births in 2007) was 
constructed to compare life-time costs and QALYs between the expanded newborn 
screening and pre-expansion newborn screening.  Estimates of costs, probabilities of 
sequelae, and utilities for disorder categories were obtained from Texas statistics, the 
literature, and expert opinion. A baseline discount rate of 3% was used for both costs and 
QALYs, with a range of 0% to 5%. Analyses were conducted from a payer’s perspective, 
so only direct medical cost estimates were included.   
The life-time incremental cost-effectiveness ratio (ICER) for expanded versus 
pre-expansion screening was about $12,000/QALY.  Probabilistic sensitivity analysis 
 viii 
using key variables showed that results ranged from about $9,500 to $13,000 /QALY.  
This range is well below the commonly cited willingness to pay threshold of 
$50,000/QALY.   
Therefore, expanded newborn screening results in additional expense to the payer 
but also improves patient outcomes by preventing avoidable morbidity and mortality.  
The screened population benefits from greater QALYs as compared to the unscreened 
population.  Overall, expanded newborn screening in Texas was estimated to be a cost-
effective option as compared to unexpanded newborn screening.   
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Chapter One - Background 
1.1  INTRODUCTION 
Newborn screening is an integral part of public health interventions in the United 
States.  It involves the screening of blood samples of newborn babies to detect genetic 
disorders of metabolism.  Screening allows healthcare providers to diagnose potentially 
serious and life-threatening disorders.  Ideally, screening should be conducted in the first 
week of a baby’s life so that treatment can be initiated before the age of four weeks.  
Early diagnosis and treatment helps prevent irreversible mental retardation, physical 
disability and death in most cases.1 
1.2  HISTORY 
The twentieth century saw the discovery of many heritable disorders that were 
metabolic in origin and could therefore be detected via biochemical testing (collectively 
called newborn screening).  Phenylketonuria (PKU), a disorder characterized by 
accumulation of unmetabolized phenylalanine in blood, was one of the first conditions to 
be described in this heterogeneous group of disorders.  Therefore, the early history of 
newborn screening is synonymous with the history of PKU screening. 2 
1.2.1  Discovery of PKU 
Phenylketonuria was first described in 1934 by Norwegian physician and 
biochemist Asbjörn Fölling.  In his research on two mentally retarded siblings, Dr. 
Fölling demonstrated that the urine of PKU-affected children contains phenylpyruvic acid 
that results from elevated levels of phenylalanine in blood.  These findings were later 
                                               
1     Therrell BL, Jr. U.S. newborn screening policy dilemmas for the twenty-first century. Mol Genet 
Metab. Sep-Oct 2001;74(1-2):64-74. 
2     Paul D. The history of newborn phenylketonuria screening in the US. Bethedsa, MD: National Institute 
of Health; 1997. 
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supported with research in eight other children.  Subsequently, Dr. Fölling also explained 
the genetic basis of the disorder.3 
1.2.2  A Simple Test for Detecting PKU 
In the early 1960s, Dr. Robert Guthrie, an American microbiologist, developed a 
simple and inexpensive bacterial inhibition assay for identifying infants with PKU.  He 
also developed a technique of collecting blood samples on filter paper which made it 
possible for the first time to implement PKU screening at the population level.4 
1.2.3  Policy Formulation 
Dr. Guthrie’s work coincided with a wave of new awareness and attitudinal 
change regarding mental retardation that had started in the 1950s.  In 1950, Nobel 
laureate and Pulitzer prize-winning author Pearl Buck wrote an article about her PKU-
stricken daughter Carol.  Buck’s article, originally published in the May 1950 issue of the 
Ladies Home Journal, later evolved into a book titled “The Child Who Never Grew.”  
Hoping for a treatment for her daughter’s illness, Buck concluded her book with the 
following words: “What has been, need not forever continue to be so.  It is too late for 
some of our children, but if their plight can make people realize how unnecessary much 
of the tragedy is, their lives, thwarted as they are, will not have been meaningless.”5 
In 1961, this new technique for diagnosing PKU was tested on 400,000 infants 
from 21 states in a trial initiated by the Children’s Bureau.  In the same year, President 
John F. Kennedy, who had a mentally retarded sister named Rosemary, promised a two-
fold increase in federal funding on retardation research.  He also appointed a Presidential 
                                               
3     Folling A. [Phenylketonuria]. Tidsskr Nor Laegeforen. Mar 1 1967;87(5):Suppl:451-454. 
4     Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations 
of newborn infants. Pediatrics. 1963;32:338-343. 
5     Buck PS. The Child Who Never Grew. New York, NY: John Day & Co; 1950. 
 3 
Advisory Commission on Mental Retardation.  In 1962, this commission recommended 
mandatory PKU screening for every newborn.  In 1963, the Children’s Bureau began 
campaigning for screening with the slogan “Test Every Newborn for PKU.”6 
Meanwhile, the lay press was rife with articles that hailed the Guthrie test as a 
major breakthrough in preventing mental retardation.  Lobbying for adoption of universal 
newborn screening gained momentum as advocacy groups like the National Association 
of Retarded Children and the March of Dimes became involved with the cause.  With 
Massachusetts as the pioneer, many states had mandated screening by 1965 (Table 1.1).7  
This adoption was surrounded with skepticism.  Opponents of mass PKU screening had 
concerns about the sensitivity and specificity of the test and believed that there was 
insufficient evidence that early detection of the disease could completely prevent mental 
retardation.  They argued that as such, PKU is a rare disorder that accounts for less than 
one percent of all cases of mental retardation.8  
                                               
6     Paul D. The history of newborn phenylketonuria screening in the US. Bethedsa, MD: National Institute 
of Health; 1997. 
7     Therrell BL, Adams J. Newborn screening in North America. J Inherit Metab Dis. Aug 
2007;30(4):447-465. 
8     Paul D. The history of newborn phenylketonuria screening in the US. Bethedsa, MD: National Institute 
of Health; 1997. 
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Table 1.1  Date Screening Mandated in US Newborn Screening Programs  


















Alabama 1965 Kentucky 1966 North Dakota 1967 
Alaska 1965 Louisiana 1964 Ohio 1965 
Arizona 1979 Maine 1965 Oklahoma 1965 
Arkansas 1967 Maryland 1965 Oregon 1963 
California 1965 Massachusetts 1963 Pennsylvania 1965 
Colorado 1965 Michigan 1965 Rhode Island 1965 
Connecticut 1965 Minnesota 1965 South Carolina 1965 
Delaware 1962 Mississippi 1985 South Dakota 1973 
District of Columbia 1980 Missouri 1965 Tennessee 1968 
Florida 1965 Montana 1965 Texas 1965 
Georgia 1966 Nebraska 1967 Utah 1965 
Hawaii 1965 Nevada 1967 Vermont 1962 
Idaho 1965 New Hampshire 1965 Virginia 1966 
Illinois 1965 New Jersey 1964 Washington 1967 
Indiana 1965 New Mexico 1966 West Virginia 1965 
Iowa 1965 New York 1964 Wisconsin 1965 
Kansas 1965 North Carolina 1983 Wyoming 1983 
Source: Therrell BL, Adams J. Newborn screening in North America. J Inherit Metab 
Dis. Aug 2007;30(4):447-465.  (Screening may have begun before the date listed as 
mandated) 
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1.3  POLICY REPORTS ON NEWBORN SCREENING 
In subsequent years, newborn screening technology continued to evolve and more 
disorders were included in the State screening panels.  Congenital hypothyroidism (CH), 
a disease more common than PKU, was one of the first disorders to be incorporated into 
the existing screening programs. Other conditions (e.g., galactosemia, homocystinuria, 
maple syrup urine disease and sickle cell disease) were also gradually added.  As newer 
techniques became available, policy makers always faced the predicament of which 
disorders to include in the universal screening panel.9 
1.3.1  Report by WHO Scientific Group (1968) 
Several policy reports have helped shape the newborn screening program as it 
exists today.  In a 2001 review article, Therrell summarized the major policy guidelines 
on newborn screening.  One of the first guidelines on this topic was issued by a World 
Health Organization (WHO) Scientific Group on Screening for Inborn Errors of 
Metabolism.  A series of five reports was published between 1964 and 1968.  The final 
recommendations of this group touched several aspects of newborn screening that were 
relevant at that time.  The use of suitable technology, automated data analysis techniques, 
and centralization of the screening process were regarded as important steps towards 
greater efficiency in the screening system.  The group also emphasized the need for 
research on the incidence of disorders and evaluation of relative efficacy of various 
screening technologies.10  A report by Wilson and Jungner was also published in 1968 
along with the work by WHO Scientific Group.  This report has been frequently used to 
help guide policy decisions.  It highlights the importance of appropriate diagnosis and 
                                               
9     Therrell BL, Jr. U.S. newborn screening policy dilemmas for the twenty-first century. Mol Genet 
Metab. Sep-Oct 2001;74(1-2):64-74. 
10     Ibid. 
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treatment options.  It also stresses that while it is important to treat the patients who have 
the disease, it is equally important to avoid harm to those who are unaffected by it.  In the 
next few years, criteria for screening were further refined.  Most notably, in his 1974 
article, Frankenburg suggested that screening should be conducted for those conditions 
where early treatment can make significant difference in disease prognosis.  Further, for 
positive cases, adequate resources for treatment should be available; and that in all 
screening initiatives, the benefits of screening should outweigh the costs.11 
1.3.2  National Academy of Sciences Report (1975) 
In 1975, the National Academy of Sciences published a comprehensive report to 
assess the current and future challenges in the implementation of genetic screening 
programs.  The highlights of this report were:12 
1. Screening for any disorder should be backed by evidence of public benefit and 
acceptance by professionals. 
2. Screening should be conducted for conditions where there are established testing 
techniques and sufficient resources for treatment, counseling and follow-up. 
3. The testing process should be within an acceptable range of expenses. 
4. Informed consent and patient education should be integrated in the screening 
program; patients should have the right to refuse screening. 
5. Education on topics related to human genetics and its application in various fields 
should receive priority. 
6. New knowledge obtained by screening should contribute to research on finding 
treatment for disorders that are untreatable. 
                                               
11     Ibid. 
12     National Academy of Sciences. Genetic Screening: Programs Principles and Research. Washington, 
DC: National Research Council .  Committee for the study of inborn errors of metabolism 1975. 
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1.3.3  The Institute of Medicine (IOM) Report (1994) 
Nearly twenty years after the NAS report, the IOM report underscored the 
importance of informed consent and also gave its stance on mandatory screening:13 
 Newborn screening only takes place 1) for conditions for which there are 
indications of clear benefit to the newborn, 2) when a system is in place for 
confirmatory diagnosis, and 3) when treatment and follow-up are available for 
affected newborns…  
The committee believes that mandatory offering of established tests (e.g., PKU, 
congenital hypothyroidism) that lead to the diagnosis of a treatable condition, is 
appropriate.  If there is no other way to ensure that affected newborns will be 
identified and have access to effective treatment (e.g., in PKU, congenital 
hypothyroidism), then mandatory newborn screening is acceptable… 
Mandatory screening should only be undertaken if there is strong evidence of 
benefit to the newborn from effective treatment at the earliest possible age (e.g., 
PKU and congenital hypothyroidism). 
1.3.4  Report from the Newborn Screening Task Force (2000)   
The American Academy of Pediatrics (AAP) organized a Newborn Screening 
Task Force in 1999.  The primary goal of this task force was to assess the problems in 
state screening programs and to suggest appropriate solutions.  The task force sought to 
address: the role of newborn screening in public health; the status of available systems of 
care; the economic aspects of screening; the ethical, legal and social implications of 
screening; and the issues pertaining to research and surveillance. 
In its final recommendations, the task force appealed to the public health systems, 
health professionals and the general public to take action so that the following goals 
could be accomplished: 
1. Federal and State responsibilities are clearly labeled. 
                                               
13     Serving the family from birth to the medical home. Newborn screening: a blueprint for the future - a 
call for a national agenda on state newborn screening programs. Pediatrics. Aug 2000;106(2 Pt 2):389-422. 
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2. Regulations and minimum standards for newborn screening systems are 
established. 
3. There are clear guidelines for healthcare professionals. 
4. There are adequate financial resources to evaluate new technologies, 
quality of care and health outcomes. 
5. The public is involved in the system that provides care to individuals as 
they go from childhood to adult lives. 
1.4  CURRENT STATUS OF NEWBORN SCREENING IN THE UNITED STATES 
In the four decades since its inception, newborn screening has evolved into an 
indispensable part of public health programs in the US as well as many other developed 
nations.  However, screening within the US is by far the most comprehensive.  What had 
started as a single test for detecting PKU has now developed into a multi-dimensional 
public health initiative.  Newborn screening programs are offered by the state 
departments of health and include the following:14 
1. Education; 
2. Screening; 
3. Follow-up and tracking; 
4. Confirmatory testing and diagnosis; 
5. Disease management; and 
6. Quality evaluation and improvement. 
Table 1.2 provides a few examples of disorders that are included in most state 
screening programs.15  These disorders have been classified as 1) core conditions, 2) core 
conditions metabolic and 3) secondary target conditions.  Details of this classification and 
screening policies by state are provided in the next section. 
                                               
14     Therrell BL, Adams J. Newborn screening in North America. J Inherit Metab Dis. Aug 
2007;30(4):447-465. 
15     Kaye C. Newborn screening fact sheets. Pediatrics 2006;118:934-963. 
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Table 1.2  Detailed Information about Disorders Commonly Diagnosed by Newborn 
Screening 
Disorder (American College of Medical 
Genetics Classification) 
Incidence Manifestations Benefits of screening 
Biotinidase Deficiency: Disorder of biotin 
(Vit. B) recycling 






Effective, low cost 
treatment is available.  So, 
unfavorable outcomes can 
be avoided 
Congenital Adrenal Hyperplasia (CAH): 
Disorder of adrenal cortex. Impaired 
cortisol biosynthesis 
1/15,981 Adrenal crisis at 3 weeks 
of age.  Vomiting diarrhea, 
failure to thrive. Mortality 
for undetected cases 
11.9% 
Prevention of adrenal crisis, 
brain damage and death. 
Prevention of wrong sex 
assignment in female 
infants, complications 
related to excess adrenal 
androgens 
Congenital Hypothyroidism (CH): 
Deficiency of thyroid hormones 
1/3,000 to ¼,000 Slow linear growth after 2-
3 months of age, loss of 
IQ, poor motor skills, 
speech disorders, cardiac 
defects, short attention 
span 
Early treatment prevents 
mental retardation 
Cystic Fibrosis (CF): Disease affecting 













Early diagnosis and 
intervention improves 
height and weight, avoids 
salt imbalance and improves 
overall prognosis 
Galactosemia: Inability to metabolize a 
simple sugar galactose (found in breast 




complications in the first 
few weeks of life, 
vomiting, diarrhea, 
jaundice, hepatomeagly. 
A diet free of galactose 
prevents initial 
complications.  Limited 
treatment for long term 
complications 
Homocystinuria: Biochemical 
abnormalities affecting trans-sulfation 
resulting most often in high concentration 
of serum methionine 
1/300,000; 
Carriers 1/135 
Arterial and renal 
thrombosis, glaucoma, 
cataracts, mental 
retardation, bone and 
muscle abnormalities 
Treatment reduces risk of 
thromboses, reduces 
incidence of mental 
retardation and decreases 
mortality 
Maple Syrup Urine Disease (MSUD): 
Also called branched chain ketoaciduria.  
Occurs due to enzyme deficiency 




Lethargy, poor feeding, 
weight loss, urine with 
“maple syrup” odor, 
seizures, coma, death 
Early diagnosis and 




Table 1.2 Continued… 
 
Disorder (ACMG Classification) Incidence Manifestations Benefits of screening 
Medium Chain Acyl-CoA Dehydrogenase 
(MCADD):  A group of 10 disorders 
affecting fatty acid oxidation.  Often 
confused with Sudden Infant Death 
Syndrome (SIDS) or Reye’s Syndrome 
1/6,400 to 
1/46,000 primarily 
in people of North 
western Europe 
Typically seen between 
ages of 3-15 months.  
Severe vomiting and 
lethargy. Long term 
complications include 
developmental problems, 
speech disorders, muscle 
weakness, seizures and 
death 
Prevents premature death 
and reduces the risk of 
similar problems within a 
family (There is a 25% 
chance of recurrence in the 
same family) 
Phenylketonuria (PKU) : Abnormally 






Inverse relationship between 
age at diagnosis and IQ.  So, 
very important to screen and 
diagnose early 
Sickle Cell Disease (SCD) and other 
disorders of hemoglobin:  Group of 
disorders in characterized by chronic 
hemolysis 







Indian and Central 
and South 
American ancestry 
Acute muscular or 
abdominal pain, 
meningitis, acute chest 
syndrome or stroke, 
anemia, jaundice and 
delayed development. 
Prevent mortality because of 
complications. 
Tyrosinemia: Type I characterized by 
liver dysfunction and Type II  
characterized by lesions in cornea 
Type I 1/100,000 
to 1/120,000. 
Type II: unknown 
incidence 
Type I: vomiting, diarrhea, 
hepatomeagly, jaundice, 
failure to thrive.  Type II: 
Disorders of the eye; 
various abnormalities of 
cornea, conjunctivitis. 
90% patients respond to 
treatment and this helps 
reduce mortality from liver 
failure 
Adapted from: Kaye, C., and the Committee on Genetics.  Newborn screening fact sheets. 
Pediatrics 2006; 118: pp 934-963  
 
 11 
1.5  SCREENING VIA TANDEM MASS SPECTROMETRY 
Tandem Mass Spectrometry (MS/MS) is one of the most important advances in 
newborn screening in the recent years.  Inborn errors of metabolism can cause one or 
more enzymes to have limited activity or to be completely absent.  In the absence of 
those enzymes, the newborn’s body is unable to breakdown amino acids or fats.  As a 
result, these compounds tend to accumulate in the blood and other tissues.  A tandem 
mass spectrometer is capable of weighing amino acids and acylcarnitines (a fatty acid 
molecule attached to a transportation system called carnitine) found in a blood sample.  It 
also calculates the amount of each of these molecules and displays the results in the form 
of vertical lines plotted on a horizontal axis called the mass spectrum.  The position of 
vertical lines along the spectrum helps identify the mass of the molecule and the height of 
the line corresponds to its quantity in the sample.  This information can help detect the 
presence of one or more metabolic errors.  (See Appendix A for a detailed view of 
images generated by MS/MS). 
1.6  STATE SCREENING PROGRAMS AND CONDITIONS DETECTED BY SCREENING 
Although newborn screening has been in place for more than forty years in the 
US, there are huge discrepancies in screening programs by state.  Variability in screening 
may arise due to differences in prevalence of a disorder, availability of treatment, 
accuracy of testing, cost-effectiveness of screening and overall budgetary decisions of a 
state.   The list of disorders screened in one state is not representative of the conditions 
covered in other states.  The conditions covered by screening are divided into three 
categories by the American College of Medical Genetics (ACMG): 
1. Core Conditions: These include hearing disorders, endocrine disorders like 
Congenital Hypothyroidism (CH) and Congenital Adrenal Hyperplasia (CAH), 
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disorders of hemoglobin such as Sickle Cell Disease (SCD), biotinidase 
deficiency, galactosemia, and Cystic Fibrosis (CF). Of all these disorders, 
screening is uniformly required by law for only CH, hemoglobin disorders (SCD 
and others) and galactosemia in all the states.  Hearing screens are required by 
law in some states but in others they are either universally offered but not 
required and in some others, they are offered only to select populations. 
Biotinidase screening is required in most states but there are a few cases where it 
is offered to select populations or is not yet implemented.   
2. Core Conditions – Metabolic:  These include fatty acid disorders such as 
Medium-chain Acyl-CoA Dehydrogenase (MCADD), organic acid disorders such 
as Glutaric Acidemia (GA), and amino acid disorders such as PKU.  Of the entire 
list of metabolic disorders, only screening for PKU is universally required by law 
in all the states.  According to the latest data from the National Newborn 
Screening and Genetic Resource Center (NNSGRC), testing for core metabolic 
conditions is required but not yet implemented in a few states namely Arkansas, 
Kansas, Montana and West Virginia.  Pennsylvania offers screening for most core 
metabolic disorders but only to select populations.  This policy may have been 
enacted for the benefit of certain native communities like the Amish and 
Mennonites. The incidence of many inborn errors of metabolism (e.g., MSUD and 
Glutaric Acidemia) is especially high in these communities due to inbreeding.16 
3. Secondary Target Conditions:  These include additional fatty acid disorders, 
organic acid disorders and amino acid disorders.  There is tremendous variation in 
state programs with respect to this category of disorders.  Screening for a certain 
                                               
16     Morton DH, Morton CS, Strauss KA. Pediatric medicine and the genetic disorders of the Amish and 
Mennonite people of Pennsylvania. AmJ Med Genetics. 2003;121C(1):5-17. 
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secondary target condition may be required by law in one state but in others, it 
may not yet be implemented and in still others, it may be offered only to select 
populations. 
The National Newborn Screening and Genetic Resource Center (NNSGRC) 
periodically updates the national newborn screening status report at its website.  A copy 
of the most recent screening status report is included in Appendix B. 
1.7  NEWBORN SCREENING EXPENDITURE AND THE ROLE OF MEDICAID 
More than one-third of the births in the US are financed by Medicaid.  These 
newborns are automatically eligible for Medicaid which covers screening and follow-up 
expenses.  The Early and Periodic Screening, Diagnosis and Treatment (EPSDT) 
program is also a part of Medicaid which provides special diets, hearing aids and 
therapies for infants who are diagnosed with one or more genetic disorders during 
screening.17 
A report from the General Accounting Office (GAO) has detailed information on 
the expenses incurred by newborn screening programs in each state.  Surveys conducted 
on individual states revealed that there was a great deal of variation in screening expenses 
incurred by various states.  In fiscal year 2001, individual states spent anywhere from 
$87,000 to $27 million on newborn screening.  States reporting very high expenditures 
had made capital investment such as procuring equipment for tandem mass spectrometry 
(MS/MS testing).  Many states reported significant increase in their fee for newborn 
screening in the last few years primarily due to program expansions.  On average, states 
spent $29.44 per child in their screening programs.  Forty-three of the fifty states charged 
a screening fee from the health care provider.  The providers were later reimbursed by 
                                               
17     Serving the family from birth to the medical home. Newborn screening: a blueprint for the future - a 
call for a national agenda on state newborn screening programs. Pediatrics. Aug 2000;106(2 Pt 2):389-422. 
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Medicaid or private health insurance.  In the remaining seven states, Medicaid was 
directly responsible for the financial burden of offering screening.18 A more detailed 
account of trends in newborn screening fee by state is provided in Appendix C. 
1.8  SCREENING IN TEXAS 
The state of Texas has several unique attributes: it is the second most populous 
state in the country and has the second highest birth rate.  It ranks third in both the 
percent of persons below the poverty level and the number of residents younger than 18 
years.  Texas also has the highest uninsured population.  These statistics pose tremendous 
challenges especially in light of the fact that Texas ranks 45th in terms of per capita 
government expenditures.  The demographics related to newborns are also equally 
daunting.  About 6,600 babies are born every week in Texas.  Of these, 1,000 are born to 
mothers receiving suboptimal prenatal care and 500 record a low birth weight.  The death 
rate for children younger than 1 year is about 50 per week.19  
Texas began newborn screening with a pilot program to screen for PKU in 1963.  
After the success of the pilot program, a 1965 statute mandated population-wide PKU 
screening in the state. In the subsequent years, the screening program saw gradual 
expansion to five conditions.  Table 1.3 provides a brief history of screening within the 
state of Texas. 
                                               
18     US General Accounting Office. Newborn Screening: Characteristics of State Programs; 2003:1-47. 
19     National Newborn Screening and Genetics Resource Center. Consultation Report Texas Newborn 
Screening Program. Austin, Texas February 28 - March 2, 2005 2005. 
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Table 1.3 History of Newborn Screening in Texas 
Condition Year Screening Was 
Initiated 
 Annual Incidence 
Within Texas 
Phenylketonuria (PKU) 1965 1:34,349 




Sickle Cell disease 1983 1:350 (in African 
Americans) 




In 2004, the Texas Newborn Screening Program reported to have received 
756,130 specimens (approximately 3,000 per day).  This number is almost twice the 
number of live births in 2004 (approximately 375,000).  This is because Texas requires 
all newborns to undergo two screens – with the first specimen collected between 24-48 
hours of age and the second specimen collected between 1-2 weeks of age.  Therefore, 
the influx of specimens sent to the newborn screening laboratory includes specimens for 
first screens, specimens for second screens and also some specimens for repeat screens 
for previously unsatisfactory specimens.  According to Texas Department of State Health 
Services (DSHS) estimates, 95% of newborns receive their first screen, and 90% receive 
both their first and second screens.20 
The newborn screening program in Texas has two sections: the specialized health 
services section and the laboratory services section.  The specialized health services 
section is comprised of the administrative, follow-up and educational services and is a 
part of the Division for Family and Community Health Services.  On the other hand, the 
laboratory services section includes the newborn screening laboratory.  In 2004, the 
administrative, follow-up and educational services received annual funding of about 
                                               
20     Ibid. 
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$700,000 from Medicaid and Title V Maternal and Child Health Block Grant funds.  The 
laboratory services section is financed via a fee-for-service plan.  This section generated 
annual revenue of $14 million through charging fees for laboratory services and through 
the sale of newborn screening kits.  The fee charged for Medicaid patients was $16.20 per 
specimen and that for non-Medicaid patients was $19.50 per specimen in 2004. Medicaid 
reimbursed the laboratory for providing services to Medicaid eligible patients.21 
1.8.1  House Bill 790 
In response to recommendations from agencies like the March of Dimes and the 
American College of Medical Genetics (ACMG), the State of Texas passed House Bill 
790 (HB 790) in 2005 which required the Department of State Health Services (DSHS) to 
implement expanded testing (which includes 27 of the 29 recommended tests) by 
November 1, 2006.22  According to the ACMG, all newborns should be screened for 9 
Organic Acid Metabolism Disorders, 5 Fatty Acid Oxidation Disorders, 6 Amino Acid 
Metabolism Disorders, 3 Hemoglobinopathies and 6 disorders that fall under the “other” 
category.  After the expansion, 19 disorders detected by MS/MS and biotinidase 
deficiency were added to the existing screening panel in Texas. The expansion of benefits 
also included dietary supplements, medications, vitamins, confirmatory testing and 
follow-up care for eligible newborns.  It was estimated that after the expansion, DSHS 
laboratory would receive approximately 800,000 specimens a year.  Follow-up would be 
required for about 15,000 abnormal screens.  Of these, 600 screens would result in 
confirmed core disorders and another 300 may be confirmed for variant or other 
                                               
21     Ibid. 
22     House Bill 790.  http://www.capitol.state.tx.us/tlo/79r/billtext/HB00790F.HTM. Accessed June 23, 
2006. 
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disorders.23  HB 790 has allocated $7.4 million for providing expanded screening in 
Texas.  Details of HB 790 can be found at:  
http://www.capitol.state.tx.us/tlo/79r/billtext/HB00790F.HTM. 
1.8.2  Overview of the Newborn Screening Process 
Although each state may differ in terms of the number of disorders included on 
the screening panel, the overall screening process is very similar.  When a newborn is 24-
48 hours old, a simple heel prick is used to draw a blood sample.  This sample is 
transferred onto a two dimensional filter paper (not in a vial).  The filter paper is a part of 
the newborn screening kit and includes space for the demographic information of the 
infant.  An example of the specimen collection form is shown in Appendix D. After being 
dried for at least four hours, the filter paper is mailed to the state laboratory.  The state 
laboratory then uses the dried blood sample for testing purposes. Many states, including 
Texas, also require a second screen at the age of 1-2 weeks.  The purpose of the second 
screen is to avoid false negative results.  With tandem mass spectrometry (MS/MS), it is 
now possible to test the same blood sample for about 50 disorders.  If a test result is 
found positive, the laboratory staff immediately notifies the case management staff.  The 
case management staff is responsible for conveying the infant’s screening results to the 
physician’s office in a timely manner since some disorders can be fatal within the first 
few days of life.  The case management staff also maintains up-to-date “FACT SHEETS” 
and “ACT SHEETS” for each of the disorders.  The fact sheets contain a description of 
the disorder and the act sheets contain information on the immediate medical 
interventions that may prevent morbidity or mortality in the affected infant.  Appendix E 
                                               
23     Drummond-Borg M. Newborn Screening. Saving lives, improving outcomes. Austin, TX: Texas 
Department of State Health Services; 2006. 
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provides an example of an abnormal test result.  Appendix F and G provide examples of 
the fact and act sheets.   
The physician’s office then notifies the infant’s family.  The family is given 
instructions on dietary restrictions, confirmatory testing and any hospitalization if 
necessary.  For example, a positive result for galactosemia means that the infant is unable 
to metabolize the milk sugar galactose. Within the first few days of life, a galactosemic 
infant may present in the emergency room with jaundice, vomiting, poor feeding and 
bacterial infections.  Upon receiving a presumptive positive screening result for 
galactosemia, the infant’s family is instructed to immediately stop feeding the baby with 
breast milk or infant formula and replace it with a soy-based diet.  This change in diet 
usually results in dramatic improvement in the infant’s health and survival.  After the 
initial notification of a positive screening result, case management also ensures regular 
follow-up of positive children.   
1.9  CRITICISM AGAINST NEWBORN SCREENING 
With rapid advances in human genetics and screening techniques, it is now 
possible to screen an infant for a large number of disorders.  However, critics believe that 
policy makers and the general public have an overly optimistic view of screening.  False 
positive results, lack of adequate treatment options and unavailability of confirmatory 
testing can lead to tremendous ethical, social and legal implications.   
In a 2006 article, Tarini et al. estimated the impact of false positive test results in 
newborn screening using birth statistics for 2004.   They reported that using a base 
estimate of 99.95% specificity for confirmatory testing for newborn screening disorders, 
approximately 25,644 infants would receive a false positive result in one year in the US.  
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Using a best case scenario of 99.995% and a worst case scenario of 99.9%, the number of 
false positives could range from 2,575 to 51,059 every year.24   
Some researchers have examined the long-lasting impact of false positive results 
on a child and his family.  It has been reported that in spite of subsequent testing that may 
confirm that the child is healthy, parents tend to remain stressed and overly protective of 
a child with a history of a false positive diagnosis.  When compared with that of children 
with normal screen results, hospitalization rates tend to be higher in the false positive 
group. 25  
While newborn screening may provide significant benefit to the truly affected 
child, it can bring unintentional harm to the false positive child and his family.  Since 
many of these disorders are rare, the number of false positives may frequently exceed the 
number of true positives.   
                                               
24     Tarini BA, Christakis DA, Welch HG. State Newborn Screening in the Tandem Mass Spectrometry 
Era: More Tests, More False-Positive Results.  Pediatrics 2006;118:448-456. 
25     Waisbren SE, Albers S, Amato S, et al. Effect of expanded newborn screening for biochemical genetic 
disorders on child outcomes and parental stress. JAMA. Nov 19 2003;290(19):2564-2572. 
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Chapter Two – Economic Studies of Newborn Screening 
2.1  INTRODUCTION  
Since the widespread adoption of newborn screening in the 1960s, policy makers 
and State Departments of Health have tried to strike a balance between offering the latest 
diagnostic techniques and economic viability.  At present, it is possible to screen 
newborns for more than 50 disorders.  Yet, most newborn screening programs offer 
population-wide screening for only 29 of those conditions.  Among other issues such as 
sensitivity and specificity of the screening test, and treatment options for positive cases, 
cost-effectiveness of screening is also a major factor that determines the inclusion of a 
diagnostic test in the screening panel.   
2.2  TYPES OF ECONOMIC ANALYSES USED TO ASSESS NEWBORN SCREENING  
Numerous studies have been conducted to evaluate the economic aspects of 
newborn screening.  Most frequently, authors have performed cost-benefit, cost-
effectiveness and cost-utility analyses.  A brief description of each of these analyses is 
provided below. 
2.2.1  Cost-benefit Analysis (CBA) 
Cost-benefit analysis (CBA) is a type of analysis where all the resources utilized 
(costs) for providing a treatment or intervention are compared with its usefulness 
(benefits).  In CBA, monetary values are assigned to both benefits and costs.  Net benefit 
is calculated by finding the difference between total costs and total benefits.  A treatment 
option is considered economically viable when the benefit-to-cost ratio exceeds 1.0.26 
                                               
26     Bootman JL, Townsend RJ, McGhan WF. Principles of Pharmacoeconomics. Third ed. Cincinnati, 
OH: Harvey Whitney Books Company; 2005. 
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2.2.2  Cost-effectiveness Analysis (CEA) 
For cost-effectiveness analysis (CEA), the resources consumed (costs) for 
providing an intervention are compared with its outcome that is measured in natural units.  
CEA differs from CBA in that it does not assign monetary values to treatment outcomes.  
Instead, outcomes may be measured in “real-life” units like number of symptom-free 
days or years of life saved.  The ratio of differential cost to that of the differential 
effectiveness (when comparing two treatment options) is called the incremental cost-
effectiveness ratio (ICER).27 
2.2.3  Cost-utility Analysis (CUA) 
Often considered a special case of CEA, cost-utility analysis examines the cost of 
a treatment relative to its effect that is measured in quality adjusted life years (QALYs).  
QALYs represent the quantity and the quality of life in a single unit.  For example, each 
year of life lived in perfect health is assigned a value of 1.0 while death is assigned a 
value of 0.  A disease state may be represented on this continuum by a value that is 
greater than 0 but less than 1.0.28  QALYs are preferred over Life Years (LYs) as an 
outcome measure because they reflect morbidity and mortality versus mortality alone. 
2.3  LACK OF UNIFORMITY IN ECONOMIC STUDIES OF NEWBORN SCREENING 
Economic analysis of newborn screening strategies is a relatively new concept 
that has been continually evolving.  It is common to encounter contradictory findings in 
the literature, especially while comparing newer studies with relatively older ones.  It is 
very important to be cognizant of the context in which each of the studies was done.  
Several factors contribute to the lack of uniformity found in the literature: 
1. Difference in alternatives being compared. 
                                               
27     Ibid. 
28     Ibid. 
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2. Conditions included (or excluded) in the analysis. 
3. Different coverage policies in different states. 
4. Disparate discounting rates used in some of the older studies. 
5. Different outcome measures used in older studies.  For example, some measures 
of outcomes such as Quality Adjusted Life Years (QALYs) are not used in older 
studies. 
6. Continuous evolution of screening technologies.  
The results of specific economic studies are summarized in this chapter. 
2.4  THE OFFICE OF TECHNOLOGY ASSESSMENT (OTA) REPORT 
A 1988 report was published by the Office of Technology Assessment (OTA) in 
response to a Congressional committee request for an assessment of cost-effectiveness of 
preventive measures for infants and children.  Newborn screening was one of the 
measures evaluated, in addition to prenatal care, well child care, accidental injuries and 
child abuse.29   
In their literature review, the OTA referred to some of the older studies that had 
evaluated the costs of Phenylketonuria (PKU) screening and some others that had 
examined the costs of screening for Congenital Hypothyroidism (CH).  Other studies that 
had evaluated the effectiveness of simultaneous screening for several disorders were also 
discussed. Most of these studies had weighed the costs of screening against the benefits 
of avoiding unfavorable outcomes and pointed to the general usefulness and cost saving 
effect of newborn screening.30 
The OTA asserted that their study was unique since it was studying the effect of 
collecting blood samples for a second screen.  They contended that the results of previous 
                                               
29     Office of Health Technology Assessment (OTA). Healthy Children: Investing in the Future 1988. 
30     Ibid. 
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studies were misleading because many important factors like costs of specimen collection 
and long-term follow-up were omitted.31  
The OTA study compared seven strategies:  the basic strategy of one specimen 
screening for Phenylketonuria (PKU) and Congenital Hypothyroidism (CH) and six other 
strategies that had one or two specimen collection points and screening for various 
combinations of PKU, CH, homocystinuria, galactosemia, and Maple Syrup Urine 
Disease (MSUD).  The basic strategy of screening all newborns for PKU and CH by 
collecting a single specimen yielded cost savings of $3.2 million/100,000 infants.  The 
combined rate of PKU and CH cases identified with screening was 34/100,000 infants 
screened.  These numbers translate into an average cost saving of $93,000 per case.  
Results of sensitivity analyses showed that these savings could range from $110,000 to 
$22,000 in best and worst case scenarios, respectively.  Assuming a screening rate of 3.7 
million newborns per year, national savings using the basic strategy could amount to 
$120 million annually.  However, the results for other strategies were not that 
encouraging.  The OTA reported that if specimens were collected twice or additional 
disorders were included in screening, then incremental costs could range from $253,000 
to $466,000 for detection and treatment of each additional case.  OTA suggested that 
additional screening (beyond PKU and CH) was a costly prospect and states should rely 
on very strong empirical evidence before including any additional tests in their screening 
panels.32 
2.4.1  Critique of the OTA Study 
In a 2004 advisory committee meeting on heritable disorders and genetic diseases 
in newborns and children, the OTA study was critiqued and it was pointed out that many 
                                               
31     Ibid. 
32     Ibid. 
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of the results of this study were not relevant anymore.  Specific points made by the 
advisory committee were:  the outcome measure used in the OTA study (number of cases 
detected) was obsolete; if healthy life years saved were used as an outcome measure,  
then the cost of screening would not be high; the study had used a discount rate of 7% 
whereas most modern studies use a rate of 3%; above all, the analysis involves older 
screening technologies which were far less effective than the current technologies.33 
The advisory committee also maintained that it is crucial to recognize additional 
factors that may help in obtaining robust analyses.  In many states, a full range of tests is 
not covered by public health agencies and private laboratories play an important role in 
screening.  Therefore, the costs incurred by these laboratories should be considered.  The 
capital investment for tandem mass spectrometry (MS/MS) equipment and specialized 
training of current employees also needs to be included in the analysis.34 
2.5  RECENT STUDIES 
Studies conducted in the last 10 years (1997-2007) have examined the economic 
implications of newborn screening with MS/MS.  Some of the studies have included only 
one or two disease states while others have incorporated the effect of screening for 
multiple conditions in a single test.  Decision tree analysis or Markov Modeling is 
frequently used for assessing the cost-benefit ratio or cost-effectiveness of screening.   
The costs included in a study can be categorized as program implementation costs, direct 
medical costs and direct non-medical costs.  Examples of costs incurred in establishing a 
population-wide screening program often includes the cost of screening (incremental cost 
of offering MS/MS), personnel, equipment, supplies, laboratory contracts, follow-up 
                                               
33     Wagner J, Ostrowsky J. OTA’s newborn screening study: relevance to today’s issues. Washington, 
DC Second advisory committee on heritable disorders and genetic diseases in newborns and children; 
September 2004. 
34     Ibid. 
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testing of false positives, and quality control for laboratories.   Other medical costs 
include inpatient, outpatient and emergency visits as well as the physician fees. Non-
medical costs include transportation expenses and wages lost by both parents.  An annual 
discount rate of 3% is used by most authors. 
Utility values ranging from 0 (for death) and 1 (for perfect health) are used as a 
qualitative measure to simultaneously reflect morbidity and mortality.  When utility 
values are multiplied by the number of years in each health state the resulting number is 
termed Quality Adjusted Life Years (QALYs). Timely detection of metabolic errors can 
increase QALYs by 0.7 to 0.8 per year.  On the other hand, false positive results can lead 
to a disutility of -0.01 to -0.03 (annualized). Since there is no documentation of the 
disutility caused by a false positive result in newborn screening, these estimates are based 
on the disutility of a false positive result in cancer studies. It may be argued that such an 
estimate may not be an accurate representation of the disutility caused by a false positive 
newborn screen result because of the unique circumstances involving a newborn and 
his/her family. Many other factors also need to be accounted for in a modeling study.  
Prevalence of a condition, proportion of asymptomatic patients, sensitivity and specificity 
of a diagnostic test, risk of mortality, and cost of confirmatory tests after an initial 
positive screen are all important variables that can affect the final result of a cost-
effectiveness study.35 36 
                                               
35     Venditti LN, Venditti CP, Berry GT, et al. Newborn screening by tandem mass spectrometry for 
medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics. Nov 
2003;112(5):1005-1015. 
36     Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. 
J Clin Oncol. Sep 15 2000;18(18):3302-3317. 
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2.6  INTERNATIONAL STUDIES ON ECONOMICS OF NEWBORN SCREENING 
Newborn screening is conducted routinely in Europe and some other developed 
nations although the number of disorders included in the screening panel varies across 
countries.  The exchange rates for the following studies were: 1Great Britain Pound 
(GBP)=0.61United States Dollar (USD) in 1997; 1GBP=0.54 USD in 2004 and in 2006.37  
The author used these exchange rates to calculate the appropriate values of USD from 
GBP.  
In a 1997 study conducted in the United Kingdom (UK), Pollitt et al. examined 
the costs and benefits of newborn screening with MS/MS.  They used a decision analytic 
model to compare cost per additional case identified, additional treatment costs per case 
for each disorder, and the cost per life-year saved.  They used a discount rate of 6% per 
annum (versus the current practice of 3% per annum).  Study results showed that for an 
annual workload of 100,000 samples, a marginal cost of £0.60 (0.98 USD) per sample 
would be incurred if the old screening technology was replaced by MS/MS.  For an 
annual workload of 50,000 samples, the marginal cost would go up to £0.87 (1.41USD) 
per sample.  An expansion of the screening program would increase the number of 
positive cases detected, which in turn would result in additional laboratory expenses.  The 
authors concluded that an expansion of the existing screening program (which included 
PKU and Congenital Hypothyroidism) would result in overall marginal costs of £18,000 
(29,340 USD) per year in the short run and £174,000 (283,620 USD) per year in the long 
run.  Population-wide screening of MCADD was declared as a financially viable option 
with a treatment cost of £31(51 USD) per life year saved.  However, screening for other 
                                               
37     FX History: historical currency exchange rates.  http://www.oanda.com/convert.fxhistory. Accessed 
September 15, 2007. 
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disorders such as tyrosinemia were not as financially attractive with a treatment cost of 
£8,339 (13,593 USD) per life year saved.38  
In an attempt to evaluate the cost-effectiveness of replacing the existing screening 
technology with MS/MS, Pandor et al. reported in 2004 that the use of MS/MS for PKU 
screening alone was not a rational choice.  However, if MCADD screening were added to 
the panel, then for an estimated range of 50,000 to 60,000 specimens annually, the 
incremental cost of screening would be -£23,312 (43,170 USD).  Additionally, for every 
100,000 newborns, an average of 59 life-years would be gained.39  These results were 
reinforced in a follow-up study conducted in 2006.  The authors reported that if MS/MS 
were used for screening for PKU and MCADD, then incremental costs of screening were 
estimated to be - £17,298 (-31,655 USD) [CI -£129,174 (-236,388 USD), to £66,434 
(121,574 USD)] per 100,000 newborns.  These savings are associated with a mean 
incremental gain of 57.3 (CI 28.0, 91.4) life years indicating that this is a dominant 
choice.40 
These results are encouraging and in line with the current scope of MS/MS 
screening.  All states in the US are adopting MS/MS for simultaneous screening of 
multiple disorders.   
2.7  STUDIES CONDUCTED IN NORTH AMERICA (UNITED STATES AND CANADA)  
Table 2.1 provides a brief description of some recent (2002-2007) economic 
analyses performed in North America.  These studies have examined the economic 
                                               
38     Pollitt RJ, Green A, McCabe CJ, et al. Neonatal screening for inborn errors of metabolism: cost, yield 
and outcome. Health Technol Assess. 1997;1(7):i-iv, 1-202. 
39     Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S. Clinical effectiveness and cost-effectiveness 
of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic 
review. Ibid.Mar 2004;8(12):iii, 1-121. 
40     Pandor A, Eastham J, Chilcott J, Paisley S, Beverley C. Economics of tandem mass spectrometry 
screening of neonatal inherited disorders. Int J Technol Assess Health Care. Summer 2006;22(3):321-326. 
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viability of various screening strategies and in general, form a consensus that newborn 
screening is a cost-effective intervention. 
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Author(s) Type of 
Analysis 





Colby and To41 
 
CUA MSUD, MCADD, Glutaric 
Aciduria, MMA, PPA, Urea cycle 
disorders, Homocystinurea 







CUA MCADD and other fatty acid 
disorders 










MCADD MS/MS screening for 
MCADD requires an 
additional $5,600/QALY 
($11,000/LY) as 






CUA PKU, CAH, CH, MSUD, 
Galactosemia, Homocystinuria, 
MCADD, biotinidase deficiency 
Multi-test screening is 
dominant approach in all 












MS/MS detectable disorders other 
than PKU 
MS/MS screening saves 
$1.5 million annually.  
Screening is the dominant 





Li et al.46 
CEA, 
CUA 
MCADD Screening for MCADD 
with MS/MS is cost-
effective based on a 
threshold value of 
$20,000 per QALY 
                                               
41     Schoen EJ, Baker JC, Colby CJ, To TT. Cost-benefit analysis of universal tandem mass spectrometry 
for newborn screening. Pediatrics. Oct 2002;110(4):781-786. 
42     Insinga RP, Laessig RH, Hoffman GL. Newborn screening with tandem mass spectrometry: 
examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. J Pediatr. Oct 
2002;141(4):524-531. 
43     Venditti LN, Venditti CP, Berry GT, et al. Newborn screening by tandem mass spectrometry for 
medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics. Nov 
2003;112(5):1005-1015. 
44     Carroll AE, Downs SM. Comprehensive cost-utility analysis of newborn screening strategies. 
Ibid.May 2006;117(5 Pt 2):S287-295. 
45     Feuchtbaum L, Cunningham G. Economic evaluation of tandem mass spectrometry screening in 
California. Ibid.:S280-286. 
46     Tran K, Banerjee S, Li H, Noorani HZ, Mensinkai S, Dooley K. Clinical efficacy and cost-
effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem 







CEA PKU and 14 other disorders Average cost of screening 
for PKU, along with 14 
other disorders is $95,000 
per life year gained. 
Abbreviations used: CBA=Cost-benefit Analysis, CEA= Cost-effectiveness analysis, 
CUA= Cost-utility Analysis, PKU=Phenylketonuria, MCADD= Medium Chain Acyl Co-
A Dehydrogenase Deficiency, CAH= Congenital Adrenal Hyperplasia, CH=Congenital 
Hypothyroidism, MS/MS=Tandem Mass Sprectrometry, QALY=Quality Adjusted Life 
Year,   MMA= Methylmalonic Acidemia, PPA=Propionic Acidemia.   
2.7.1  Schoen et al. (2002) 
In a 2002 study on universal newborn screening using MS/MS, Schoen et al. 
examined the costs and benefits of the program in a California-based Health Maintenance 
Organization (HMO).  Under the costs of screening, the authors included cost of 
screening, cost of hospital stay, cost of special diet and treatment costs for the first five 
years of a child’s life.  Whenever appropriate, these costs were compared for early versus 
late detection of inborn errors of metabolism (IEMs) (Table 2.2).  In addition, an average 
cost of $1,000 was assigned to each false positive result for various IEMs.  This cost 
included the cost of test itself, follow up by a genetics nurse, visit to an urgent care clinic, 
confirmatory lab tests, visit to the emergency room (ER) and/or hospital stay (Table 2.3).  
The only exception was MCADD where the cost of a false positive result was estimated 
at $200 since no immediate medical treatment is warranted in this case.48 
                                               
47     Cipriano LE, Rupar CA, Zaric GS. The cost-effectiveness of expanding newborn screening for up to 
21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. 
Value in Health. Mar-Apr 2007;10(2):83-97. 
48     Schoen EJ, Baker JC, Colby CJ, To TT. Cost-benefit analysis of universal tandem mass spectrometry 
for newborn screening. Pediatrics. Oct 2002;110(4):781-786. 
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It was estimated that in the base case scenario, screening would cost 
$5,827/QALY with a range of $736 to $11,419/QALY for the best and worst case 
scenarios respectively (Table 2.4). 
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Table 2.2 Estimated Base Costs Associated with Newborn Screening – Schoen et al.49 
Cost Category Estimated Value 
Cost of screening $15 
Hospital stay (early detection) $4,000 
Hospital stay (late detection) $8,000 
Five-year treatment cost (early detection) $64,116* 
Five –year treatment cost (late detection) $93,884** 
Cost of special diet for patients younger than 5years $10,000 
Cost of special diet for patients older than 5years $2,500 
*=assumed $0 for MCADD; **=Assumed $0 for MCADD and $118,884 for MSUD 
 
Table 2.3  Estimated Costs of False-Positive Test Results – Schoen et al.50 
Cost Category Estimated Value 
Response by genetics nurse $100 
Visit to urgent care $110 
Laboratory tests $600 
Visit to ER $200 
Hospital stay $2,000 
 
                                               
49     Ibid. 
50     Ibid. 
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Table 2.4 Cost Per Quality Adjusted Life Year Saved by Screening – Schoen et al.51 
Scenario Cost/Patient QALY/Patient                  Cost Per QALY 
Base Case $15.49 0.0026 $5,827 
Least Favorable $27.39 0.0024 $11,419 
Most Favorable $2.23 0.0028 $736 
2.7.2  Insinga et al. (2002) 
In an incremental cost-utility study on a hypothetical cohort of 100,000 infants, 
Insinga et al. examined the impact of introducing MS/MS screening in Wisconsin.  The 
authors focused only on the outcomes of being able to screen for MCADD using MS/MS.  
There are several reasons why a number of studies have been conducted on this one 
disorder:  MCADD is a relatively common metabolic error having an incidence rate 
similar to that of PKU (approximately 1 in 11,000 to 1 in 15,000); MS/MS screening 
offers a high degree of sensitivity (0.95 to 1.0) and specificity (0.995 to 1.0) for MCADD 
detection; if detected early, it is a highly treatable disorder with very good patient 
outcomes.52 Screening for MCADD is therefore expected to provide a relatively high 
benefit from a societal perspective.   
In this study, costs pertaining to incremental cost of screening, confirmation of 
positive or negative screening test, special diet for a life-time, follow-up testing and 
physician visits, hospital admission and possible neurological impairment were included. 
Confirmatory testing for a positive screen may involve additional tests to determine the 
                                               
51     Ibid. 
52     Insinga RP, Laessig RH, Hoffman GL. Newborn screening with tandem mass spectrometry: 
examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. J Pediatr. Oct 
2002;141(4):524-531. 
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exact genetic basis of the disease.  A breakdown of base-case cost estimates is shown in 
Table 2.5.    
Table 2.5 Base Case Cost Estimates – Insinga et al. 53 
Cost Category Estimated Value 
Incremental cost of MS/MS screening $3.99 
MS/MS test confirmation (positive for MCADD) $1,715 
MS/MS test confirmation (negative for MCADD) $1,465 
Added lifetime carnitine supplementation cost per child $10,678 
Added lifetime follow-up testing and visit cost per child $12,427 
Cost per routine hospital admission $2,833 
Cost per case of neurologic impairment $552,000 
Assuming utility values of 0.06 and 0.67 with severe and mild neurological 
impairment respectively, the study included QALYs gained as the outcome measure. 
Results of the cost-utility analysis showed that the net cost of screening for MCADD 
alone was $401,879 with a total gain of 9.6 QALYs.  This yields an incremental cost-
effectiveness ratio (ICER) of $41,862/QALY which is below the threshold of 
$50,000/QALY as per the established practice for assessing the effectiveness of a new 
intervention (Table 2.6).  In practice, the newborn screening panel would include more 
disorders which would result in a lower cost per QALY.54 
                                               
53     Ibid. 
54     Ibid. 
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Table 2.6 Base Case Cost-effectiveness Estimates – Insinga et al.55 
Cost Category Estimated Value 
Total Costs $526,079 
Cost Savings -$124,200 
Net cost of screening for MCADD $401,879 
QALYs gained from prevented deaths          5.8 
QALYs gained from prevented severe neurological impairment          2.8 
QALYs gained from prevented mild neurological impairment         1.0 
Total QALYs gained from screening         9.6 
Cost-effectiveness Ratio $41,862/QALY 
2.7.3  Venditti et al. (2003) 
In a simulation study using primary data from retrospective chart reviews, 
patient/family interviews, expert opinion and secondary data from the literature, Venditti 
et al. tracked the outcomes of screening of infants from birth through adulthood.  Their 
primary model made predictions for the first twenty years of life and then another 
simulation studied the outcomes until 70 years.56  The model included cost of screening, 
cost of follow up and confirmatory tests for presumptive positive patients, treatment for 
MCADD and related complications, inpatient, outpatient and emergency room visits 
(Table 2.7). 
                                               
55     Ibid. 
56     Venditti LN, Venditti CP, Berry GT, et al. Newborn screening by tandem mass spectrometry for 
medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics. Nov 
2003;112(5):1005-1015. 
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Table 2.7 Costs Incurred in Screening (range used in sensitivity analyses) – Venditti et 
al.57 
Cost Category Estimated Value 
Screening and follow up by newborn screening program           $4 ($1-$20) 
Confirmatory testing  for final diagnosis of a positive screen result $2,120 ($0-$5,000) 
Carnitine treatment for patients diagnosed with MCADD       $0 ($0-10,000) 
Care for severely affected $1,914 ($0-$4,000) 
It was assumed that the utility of being healthy was 1.0 and the utility of being 
diagnosed with MCADD via screening and confirmatory testing was also very close to 
1.0 (0.99).  Utility for unscreened patients who were diagnosed on the basis of symptoms  
was estimated at 0.88 and that for undiagnosed patients was estimated at 0.65. 
Annualized disutility of a false positive was estimated to range between -0.01 and -0.03.  
Although no formal studies have been performed to assess the disutility of false positives 
in metabolic disorders, results from cancer studies were used to estimate the disutility of 
the anxiety caused by a false positive MCADD diagnosis. 20  
Threshold values for C/E ratios were also based on reports in the literature.  
Results of the study showed that over a period of 20 years, the cost of newborn screening 
for MCADD was $5,600 per QALY (Table 2.8).  Simulation modeling at a 70-year 
horizon showed that MCADD screening cost only $100 per QALY. These results 
indicate that over a longer term, screening is a very cost-effective measure. 20 
                                               
57     Ibid. 
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Table 2.8 Base case Cost-effectiveness and Projections on a 20 year Horizon for the 
2001 US Newborn Cohort (4,040,121 infants) – Venditti et al.58 
Variables With Screening Without Screening Difference 
Total cost $19,009,981 $13,485,520 $5,524,461 
Total effectiveness 
(LYs) 
57,951,023 LYs 57,950,522 LYs 501 LYs 
Total effectiveness 
(QALYs) 
57,950,983 QALYs 57,949,993 QALYs 990 QALYs 
Average cost per 
neonate 
$4.7053 $3.3379 $1.3674 
Average effectiveness 
per neonate (LYs) 
14.343883 LYs 14.343759 LYs 0.000124 LYs 
Average effectiveness 
per neonate (QALYs) 
14.343873 QALYs 14.343628 QALYs 0.000245 QALYs 
Incremental cost-effectiveness ratios : Cost/LY saved (95% CI) = $11,000 
                                                              Cost/QALY saved (95% CI) = $5,600 
2.7.4  Carroll and Downs (2006)  
In a 2006 study on the cost-effectiveness of including a broad MS/MS testing into 
a newborn screening program, a comparison was drawn between individual screening 
tests for seven metabolic disorders and simultaneous screening with MS/MS.  Assuming 
that the MS/MS screening panel would include PKU, biotinidase deficiency, MSUD, 
galactosemia, MCADD and homocystinuria, the authors compared three alternative 
strategies: no screening; screening with MS/MS; and screening with individual tests 
designed to detect PKU, CAH, CH, biotinidase deficiency, MSUD, galactosemia and 
homocystinuria.59  
Table 2.9 shows the costs incurred when each of the disorders is screened 
individually or simultaneously (using MS/MS).  The study took a societal perspective and 
included start up costs, operating costs, life-time treatment costs and costs of sequeale. 
Estimates of life-time treatment costs for each of the disorders and the costs of common 
                                               
58     Ibid. 
59     Carroll AE, Downs SM. Comprehensive cost-utility analysis of newborn screening strategies.  May 
2006;117(5 Pt 2):S287-295. 
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sequeale of are shown in Tables 2.10 and 2.11 respectively.  These tables also include the 
threshold values (obtained from sensitivity analysis) at which the tests are “no longer cost 
saving”. In the decision analysis, a “multiplicative utility model” was used where utilities 
of all the possible complications were multiplied to account for >1 complications in the 
possible outcomes.  Life expectancy estimates for disabilities were derived from the 
literature.   
A comparison was drawn between various screening strategies and not screening. 
Results showed that a combined screening panel with MS/MS was the most dominant 
strategy where the incremental cost of screening was -$43 per screen.  Even when 
individual screening tests were performed for each of the disorders, screening still 
dominated the “no screening” strategy. The only exceptions were testing for CAH and 
GAL which cost $20,000 per QALY gained and $94,000 per QALY gained, respectively.  
However, if a conventional benchmark of $50,000 per QALY gained is used, then even 
the CAH test would be deemed cost-effective.  MS/MS screening was found to be the 
least expensive screening method (Table 2.12).60  Like most other studies, this study also 
underscored the importance of sensitivity and specificity of the screening method since 
false positive results can lead to substantial costs.  A high false positive rate ultimately 
translates into lack of cost-effectiveness. 
                                               
60     Ibid. 
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Table 2.9 Cost Comparison of Various Screening Tests – Carroll and Downs61 
Type of Screening Test Base Case Costs ($) Threshold Values 
obtained from 
Sensitivity Analysis 
Biotinidase $1.83 $14.00 
Congenital Adrenal Hyperplasia $3.63 Not listed 
Congenital Hypothyroidism $4.59 $8.70 
Galactosemia $3.79   Not listed 
Homocystinurea $0.84 $2.45 
Maple Syrup Urine Disease $2.49 $2.90 
Phenyl Ketonurea $3.43 $38.20 
MS/MS $16.02 $58.00 
Follow-up (any false positive) $300.00 Range $600 to $10,000 
Table 2.10 Lifetime Cost of Treatment of Various Inborn Errors of Metabolism – 
Carroll and Downs62 
 
                                               
61     Ibid. 
62     Ibid. 
Name of Disorder Base Case Costs ($) Threshold Values 
Obtained from 
Sensitivity Analysis 
Biotinidase $6,592 Not listed 
Congenital Adrenal Hyperplasia $10,000 Not listed 
Congenital Hypothyroidism $9,439 Not listed 
Galactosemia $9,439 Not listed 
Homocystinurea $122,515 Not listed 
MCADD $10,173 Not listed 
Phenyl Ketonurea $122,515 Not listed 
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Table 2.11 Life-time Cost of Various Sequeale of Inborn Errors of Metabolism – 
Carroll and Downs63 
Table 2.12 Overall Cost-effectiveness of Various Screening Strategies Compared with 







MS/MS testing -$43 0.004 0.72 Dominates 
PKU test -$35 0.00306 0.81 Dominates 
BIOT test -$13 0.0005 1.1 Dominates 
CH  test -$5 0.00314 1.21 Dominates 
HCY test -$2 0.00019 1.24 Dominates 
MSUD test -$1 0.0002 1.26 Dominates 
No test   1.26  
GAL test $5 0.00005 1.32 $94,000 
CAH test $6 0.00028 1.34 $20,357 
2.7.5  Feuchtbaum and Cunningham (2006) 
This study is based on an economic evaluation of the annual costs of MS/MS 
screening of 540,000 infants born in California in one year.  Table 2.13 describes the 
annualized costs incurred for MS/MS screening in California. 
                                               
63     Ibid. 
64     Ibid. 
Type of Sequelae Base Case Cost 
($) 
Threshold Values 
Obtained from Sensitivity 
Analysis 
Blindness $581,688 $180,000 
Hospitalization before death $27,809 Not listed 
MCADD crisis $308,315 Not listed 
Deafness $445,255 Not listed 
Mild developmental delay $44,192 $3,000 
Moderate developmental delay $77,079 Not listed 
Severe developmental delay $1,042,110 $450,000 to $685,000 
Moderate cerebral palsy $77,079 Not listed 
Severe cerebral palsy $216,848 $540,000 
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Table 2.13 Incremental Annualized Costs for MS/MS Screening in California  
Feuchtbaum and Cunningham65 
Cost Category Cost Estimate (for 540,000 infants) 
Personnel and administration $540,000 
Equipment  $500,000 
Supplies $2,012,500 
Laboratory contracts $1,870,000 
Follow-up $742,000 
Total $5,664,500 
The study estimated that the total cost of screening was $5.7 million.  However, 
screening would save $7.2 million in treatment costs avoided.  This would result in a net  
saving of $1.5 million. If the value of lives saved were included, the benefit-to-cost ratio 
for MS/MS screening was estimated at $9.32:1 ($11.67:1 under best case and $4.34:1 
under worst case scenarios).66 
Results of cost utility analysis of MS/MS screening are presented in Table 2.14. 
                                               
65     Feuchtbaum L, Cunningham G. Economic evaluation of tandem mass spectrometry screening in 
California. S280-286. 
66     Ibid. 
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Table 2.14 Cost-utility Analysis of MS/MS Screening in California for 540,000 Infants 
- Feuchtbaum and Cunningham67 
Estimates of marginal 
cost per QALY 




949 1,221 259 
Cost per QALY (with 







Cost per QALY (with 





Cost per QALY (with 








2.7.6  Tran et al. (2007)  
In a 2006 study based in Canada, Tran et al. studied the cost-effectiveness and 
clinical efficacy of newborn screening for MCADD using tandem mass spectrometry 
(MS/MS).  The authors did not explicitly provide a break-down of all the costs included 
in their analysis.  According to the study projections, for a hypothetical birth cohort of 
330,803 infants (the birth rate in Canada for year 2003 – 2004), screening would cost 
C$934,923 (USD 719,890) over a 77-year horizon.  Over the same period, the cost of not 
screening was estimated at C$450,521 (USD 346,901).  Therefore, the incremental cost 
of screening is C$484,202 (USD 372,835).  The study also estimated that screening 
would result in an additional 181 QALYs.  The overall ICER for the base case was 
estimated at C$2,676/QALY (USD 2,060/QALY) gained.68  Details of the economic 
                                               
67     Ibid. 
68     Tran K, Banerjee S, Li H, Noorani HZ, Mensinkai S, Dooley K. Clinical efficacy and cost-
effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem 
mass spectrometry. Clin Biochem. Feb 2007;40(3-4):235-241. 
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analysis presented in this study are shown in Table 2.15.  The currency conversion rate 
for 2004 was 1C$ = 0.77 USD.69 
Table 2.15 Results of Economic Analysis of Screening for MCADD Versus No 
Screening – Tran et al.70 
Type of Analysis ICER (C$ per QALY) 
Base Case, Best and Worst Scenarios  
Base case C$2,676/QALY 
Best case C$1,029/QALY 
Worst case C$11,463/QALY 
One-way Sensitivity Analysis  
Screening cost C$(0.50 – 5.60) Dominant (<0) to 6,963 
Specificity (99.95 – 99.995) C$3,095 to C$2,078/QALY 
Cost of acute episode C$ (10,000 – 20,000) C$2,585 to C$1,974/QALY 
Incidence (1:20,000 – 1:14,286) C$2,952 to C$1,647/QALY 
Management cost C$(1,500 – 4,000) C$2,150 to C$2,367/QALY 
Cost of severe neurological impairment 
C$(100,000 – 250,000) 
C$2,601 to C$1,960/QALY 
2.7.7  Cipriano et al. (2007) 
In a recent study Cipriano et al. examined the costs of expanding the newborn 
screening program in Ontario, Canada.  In a decision analytic model that compared 
screening for individual disorders with screening the various disorders in groups of up to 
21 conditions, costs and health benefits were compared for a hypothetical cohort of 
130,000 newborns in Ontario in one year.  The study included an account of start-up 
costs if the provincial newborn screening program were to be expanded.  Other costs 
considered included estimates of per capita health care costs (stratified by different age 
groups), hospitalization costs, costs associated with additional healthcare services, costs 
                                               
69     FX History: historical currency exchange rates.  http://www.oanda.com/convert.fxhistory. Accessed 
September 15, 2007. 
70     Tran K, Banerjee S, Li H, Noorani HZ, Mensinkai S, Dooley K. Clinical efficacy and cost-
effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem 
mass spectrometry. Clin Biochem. Feb 2007;40(3-4):235-241. 
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of diagnostics, costs of non-dietary as well as dietary treatments, costs of pharmaceutical 
treatments, costs of education and social services.  It was assumed that an unscreened 
infant would show symptoms of the disorder which would then be diagnosed via clinical 
presentation.  The cost of such a clinical diagnosis was estimated to be C$4,389 (2004 
Canadian dollars).71  This is equivalent to USD 3,380, based on a currency conversion 
rate of 1C$ = 0.77 USD.72 All costs considered in the study are outlined in Table 2.16. 
                                               
71     Cipriano LE, Rupar CA, Zaric GS. The cost-effectiveness of expanding newborn screening for up to 
21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. 
Value in Health. Mar-Apr 2007;10(2):83-97. 
72 {,  #73} 
 45 
Table 2.16 Base case Values and Costs of Screening Program, Healthcare, 
Hospitalization, Education and Social Services. (Costs in 2004 C$)  
Cipriano et al.73 
Cost Category Estimated Value 
Cost of clinical diagnosis C$4,389 
Cost of Screening  
Annual equipment cost C$490,380 
Average staff expense per sample C$0.85 
Reagents and consumables per sample C$13.46 
Average Per Capita Healthcare Costs  
Average healthcare costs (<1 year) C$5,211 
Average healthcare costs (1-4 years) C$800 
Average healthcare costs (5-14 years) C$693 
Average healthcare costs (15-19 years) C$1,089 
Average healthcare costs (20-44 years) C$1,825 
Average healthcare costs (45-64years) C$4,244 
Average healthcare costs (65-79years) C$7,736 
Average healthcare costs (80+ years) C$14,417 
Hospitalizations  
Emergency room visit C$1,167 
Inpatient hospitalization, patient under 10 years C$2,055 
Inpatient hospitalization, patient over 10 years C$1,765 
Additional Health Care Services  
Initial call to schedule appointment (15-minute call 
with registered nurse) 
C$7.03 
Initial specialist consultation (all presumptive 
positives) 
C$122.00 
Subsequent pediatrician and specialist 
appointments (per appointment) 
C$73.85 
Registered dietician appointment (per 60-minute 
appointment) 
C$75.96 
Initial genetic counseling appointment (in the year 
of diagnosis) 
C$238.20 
Follow-up genetic counseling appointment (3 
years after initial diagnosis) 
C$100.90 
Maintenance Diagnostics  
Quantitative amino acid diagnosis C$108 
Urine organic acids C$108 
Abdominal ultrasound C$339 
Non-dietary Treatments  
Hemodialysis – initial acute C$1,045.15 
Hemodialysis – chronic or repeat C$537.40 
Liver transplant C$67,965.85 
                                               
73     Cipriano LE, Rupar CA, Zaric GS. The cost-effectiveness of expanding newborn screening for up to 
21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. 
Value in Health. Mar-Apr 2007;10(2):83-97. 
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Kidney transplant C$32,593.30 
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Table 2.16 Continued 
 
Pharmaceutical Treatments (approximate 
annual costs) 
 
Arginine (660mg/kg/day) C$41,063 
Ascorbic acid (100mg/day) C$30 
Betaine (6g/day) C$73 
Carbamazepine (200mg/day) C$90 
Coalmine (1.5mg/day) C$1,700 
Cysteine (6g/day) C$5,724 
Glycine (375mg/kg/day) C$685 
L-carnitine (100mg/kg/day) C$7,565 
Medium chain triglycerideoil (120ml/day) C$4,380 




Pyridoxine (300mg/day) C$82 
Riboflavin (200mg/day) C$58 
Sodium phenyl butyrate (500mg/kg/day) C$71,237 
Thiamine (500mg/day) C$3,980 
Dietary Treatments  
Elemental formula (year 0) C$4,000 
Elemental formula (year 1-8) C$5,000 
Elemental formula (year 8-16) C$6,000 
Elemental formula (over 16 years) C$5,000 
Low protein foods (1-8 years) C$2,000 
Low protein foods (> 8 years) C$3,500 
Education and Social Services  
Standard education (5-18 years) C$7,500 
Additional classroom support C$18,000 
Advanced classroom support C$27,000 
Living in an assisted living facility C$18,000 
Living in an institutional facility C$36,000 





Study results showed that in the base case, if the province of Ontario implemented 
MS/MS screening for PKU alone, it would cost an additional C$2.26 million (USD 1.74 
million) annually.  This strategy has an ICER of C$5,492,114 (USD 4,228,928) per life-
year gained.  Costs were estimated for incremental addition of one disorder at a time.  It 
was estimated that screening for a group of disorders that included PKU and 14 other 
conditions would cost less than C$70,000 (USD 53,900) per life year gained.  The 
incremental cost of including each of these disorders in the panel was less than 
C$100,000 (USD 77,000) per life year gained.  However, the incremental cost spiked to 
C$309,400 (USD 238,238) per life year for the 15th disorder.  It is likely that the 
sequence in which individual disorders were added to the screening panel was based on 
incidence and expected treatment costs.  It was estimated that screening in groups (versus 
screening for each individual disorder) is a more cost-effective strategy (Table 2.17).  
However, not all disorders that can be detected via MS/MS are financially viable options 
for a newborn screening panel.74 
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2.8  SUMMARY OF STUDIES 
The studies conducted so far support the cost-effectiveness of newborn screening 
with MS/MS.  There is an agreement that simply replacing the Guthrie test for PKU with 
MS/MS is not cost-effective.  However, if multiple disorders are included in the 
screening panel, the incremental cost is not very high.  Therefore, in the long run, it is 
possible to offset or reduce the costs incurred in screening.  However, there is little 
uniformity in terms of the disorders included, the likelihood of some of the adverse 
outcomes, the costs included and the range of these costs.  Inclusion or exclusion of 
certain disorders in an economic analysis can lead to different cost and outcome 
estimates.  Study results would also differ if indirect costs such as productivity loss are 
included in the estimate.  There are also variations in the dollar value of some treatment 
costs as well as the likelihood of some of the sequelae.  All of these variations can lead to 
different results.  Despite these differences, most study results are below the commonly 
used threshold of $50,000/QALY.  
2.9  STUDY RATIONALE AND OBJECTIVES 
From the above review of literature, it becomes clear that newborn screening is a 
multifaceted topic with clinical, ethical, legal and economic implications.  All of these 
aspects need to be researched, especially in the light of recent expansions in the newborn 
screening panels being offered by state health services across the country.  Among other 
factors, the ability to test for multiple disorders is closely tied with the need for additional 
resources for confirmatory testing, long-term treatment and disease management.  Timely 
diagnosis and treatment are likely to result in reduced morbidity and mortality associated 
with these rare but serious disorders. After the latest expansion in the Texas newborn 
screening panel, a systematic health economic analysis is warranted to understand the 
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long-term implications (in terms of costs and patient outcomes) of this important policy 
decision.  This study is intended to estimate the cost-effectiveness of expanded newborn 
screening in Texas and to answer related questions.  The objectives of this study are:  
1. To describe the demographic characteristics of the infant population served by the 
Texas newborn screening program; 
2. To describe the incidence of various disorders since the expansion of the newborn 
screening program in Texas and compare the incidence of each disorder with the 
estimates published in the literature; 
3. To estimate the average input cost to the state for providing expanded screening 
and confirmatory testing for positive screens; 
4. To estimate the average costs of follow-up and treatment for infants who test 
positive (by disorder); 
5. To estimate the average QALYs for infants who test positive (by disorder) and 
draw a comparison between expanded and pre-expansion strategies; and 
6. To estimate whether the expanded newborn screening program in Texas is cost-
effective. 
2.10  STUDY HYPOTHESES 
This section provides details about the hypotheses that were developed for the 
above study objectives.  Of the six objectives, hypotheses were developed for objectives 
4, 5 and 6.    
2.10.1  Hypotheses for Objective One 
The first objective was to describe the demographic characteristics of the infant 
population served by the Texas newborn screening program.  Data is available about the 
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demographic characteristics of Texas births for 2005.  No hypothesis is needed for this 
objective. 
2.10.2  Hypotheses for Objective Two 
The incidence of the newly added disorders in the Texas newborn screening panel 
has only been recorded since the program expansion in 2007.  This information was 
obtained from the Texas Department of State Health Services (DSHS).  No hypothesis is 
needed for this objective. 
2.10.3  Hypotheses for Objective Three  
Average costs associated with expanded newborn screening and confirmatory 
testing were obtained from DSHS and Institute of Metabolic Disease at Baylor Research 
Institute.  No hypothesis is needed for this objective. 
2.10.4  Hypotheses for Objective Four 
Average direct medical costs associated with follow-up and treatment such as  
cost of special diet and medications, inpatient and outpatient expenses were compared 
between the expanded and pre-expansion screening strategies.   
H4.1  Cost ASA_CIT expanded screening ≥ Cost ASA_CIT pre-expansion screening 
Average direct medical costs associated with follow-up and treatment of 
Arginosuccinic aciduria (ASA) and Citrullinemia (CIT) for the expanded 
screening strategy are greater than or equal to the average direct medical 
costs for the pre-expansion strategy. 
H4.2   Cost HCY expanded screening ≥ Cost HCY pre-expansion screening 
Average direct medical costs associated with follow-up and treatment of 
Homocystinuria (HCY) for the expanded screening strategy are greater 
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than or equal to the average direct medical costs for the pre-expansion 
strategy. 
H4.3   Cost TYR expanded screening ≥ Cost TYR pre-expansion screening 
Average direct medical costs associated with follow-up and treatment of 
Tyrosinemia (TYR) for the expanded screening strategy are greater than or 
equal to the average direct medical costs for the pre-expansion strategy. 
H4.4   Cost MCADD expanded screening ≥ Cost MCADD pre-expansion screening 
Average direct medical costs associated with follow-up and treatment of 
Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) for the 
expanded screening strategy are greater than or equal to the average direct 
medical costs for the pre-expansion strategy. 
H4.5   Cost GA I expanded screening ≥ Cost GA I pre-expansion screening 
Average direct medical costs associated with follow-up and treatment of 
Glutaric Acidemia type I (GA I) for the expanded screening strategy are 
greater than or equal to the average direct medical costs for the pre-
expansion strategy. 
H4.6   Cost MSUD expanded screening ≥ Cost MSUD pre-expansion screening 
Average direct medical costs associated with follow-up and treatment of 
Maple Syrup Urine Disease (MSUD) for the expanded screening strategy 
are greater than or equal to the average direct medical costs for the pre-
expansion strategy. 
H4.7   Cost COAD expanded screening ≥ Cost COAD pre-expansion screening 
Average direct medical costs associated with follow-up and treatment of 
Classical Organic Acid Disorders (COAD) for the expanded screening 
 55 
strategy are greater than or equal to the average direct medical costs for 
the pre-expansion strategy. 
H4.8   Cost OVERALL expanded screening ≥ Cost OVERALL pre-expansion screening 
Overall direct medical costs associated expanded screening strategy are 
greater than or equal to the overall direct medical costs for the pre-
expansion strategy. 
2.10.5  Hypotheses for Objective Five 
The Quality Adjusted Life Years (QALYs) were compared between the expanded 
and pre-expansion screening strategies.   
H5.1   QALYs ASA_CIT expanded screening ≥ QALYs ASA_CIT pre-expansion screening 
The average QALYs for Arginosuccinic aciduria (ASA) and Citrullinemia 
(CIT) patients  diagnosed via expanded screening are greater than or equal 
to those for ASA and CIT patients diagnosed via pre-expansion screening. 
H5.2  QALYs HCY expanded screening ≥ QALYs HCY pre-expansion screening 
The average QALYs for Homocystinuria (HCY) patients diagnosed via  
expanded screening are greater than or equal to those for HCY patients  
diagnosed via clinical symptoms pre-expansion screening. 
H5.3   QALYs TYR expanded screening ≥ QALYs TYR pre-expansion screening 
The average QALYs for Tyrosinemia (TYR) patients diagnosed via 
expanded screening are greater than or equal to those for TYR patients 
diagnosed via pre-expansion screening. 
H5.4   QALYs MCADD expanded screening ≥ QALYs MCADD pre-expansion screening 
The average QALYs for Medium Chain Acyl-CoA Dehydrogenase 
Deficiency (MCADD) patients diagnosed via expanded screening are 
 56 
greater than or equal to those for MCADD patients diagnosed via pre-
expansion screening. 
H5.5   QALYs GA I expanded screening ≥ QALYs GA I pre-expansion screening 
The average QALYs for Glutaric Acidemia (GA I) patients diagnosed via 
expanded screening are greater than or equal to those for GA I patients 
diagnosed via pre-expansion screening. 
H5.6   QALYs MSUD expanded screening ≥ QALYs MSUD pre-expansion screening 
The average QALYs for MSUD patients diagnosed via screening are 
greater than or equal to those for MSUD patients diagnosed via pre-
expansion screening. 
H5.7   QALYs COAD expanded screening ≥ QALYs COAD pre-expansion screening 
The average QALYs for Classical Organic Acid Disorders (COAD) 
patients diagnosed via screening are greater than or equal to those for 
COAD patients diagnosed via pre-expansion screening. 
H5.8   QALYs OVERALL expanded screening ≥ QALYs OVERALL pre-expansion screening 
The overall QALYs for patients diagnosed via screening are greater than 
or equal to those for patients diagnosed via pre-expansion screening. 
   
2.10.6  Hypotheses for Objective Six 
A ceiling cost ratio (Rc) is often used as a threshold of cost-effectiveness value.  
The Rc for this study is equivalent to the willingness to pay (WTP) for an additional 
quality adjusted life year (QALY) in a child affected with one of the inborn errors of 
metabolism.  In previous studies, a WTP of $50,000/QALY has been used which is also 
consistent with the convention in the Health Economics literature in general.  The 
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Incremental Cost-effectiveness Ratio (ICER) for expanded screening strategy was 
compared with the pre-expansion screening strategy.   
H6.1  ICER ASA_CIT expanded screening versus pre-expansion screening ≤ Rc 
The ICER of expanded versus pre-expansion screening for ASA and CIT 
is less than or equal to the Rc of $50,000/QALY 
H6.2   ICER HCY expanded screening versus pre-expansion screening ≤ Rc 
The ICER of expanded versus pre-expansion screening for HCY is less 
than or equal to the Rc of $50,000/QALY 
H6.3  ICER TYR expanded screening versus pre-expansion screening ≤ Rc 
The ICER of expanded versus pre-expansion screening for TYR is less 
than or equal to the Rc of $50,000/QALY 
H6.4  ICER MCADD expanded screening versus pre-expansion screening ≤ Rc 
The ICER of expanded versus pre-expansion screening for MCADD is 
less than or equal to the Rc of $50,000/QALY 
H6.5  ICER GA I expanded screening versus pre-expansion screening ≤ Rc 
The ICER of expanded versus pre-expansion screening for GA I is less 
than or equal to the Rc of $50,000/QALY 
H6.6  ICER MSUD expanded screening versus pre-expansion screening ≤ Rc 
The ICER of expanded versus pre-expansion screening for MSUD is less 
than or equal to the Rc of $50,000/QALY 
H6.7  ICER COAD expanded screening versus pre-expansion screening ≤ Rc 
The ICER of expanded versus pre-expansion screening for COAD is less 
than or equal to the Rc of $50,000/QALY 
H6.8  Overall ICER expanded screening versus pre-expansion screening ≤ Rc 
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The overall ICER of expanded versus pre-expansion screening for is less 
than or equal to the Rc of $50,000/QALY  
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Chapter Three - Methodology 
This chapter provides a detailed account of the study methodology.  It consists of 
six sections.  Section one includes a description of the sources of data that were used in 
this study.  Section two is comprised of a brief discussion of the study population and the 
inclusion and exclusion criteria.  Section three covers the theoretical basis of economic 
evaluation in healthcare and includes a section on the theory behind cost-effectiveness 
analysis. Section four discusses the general concepts of decision analysis and a detailed 
description of the vital elements of Markov modeling. Section five contains an overview 
of categories of costs used in the cost-effectiveness analysis. Section six contains tabular 
representations of the estimated costs, probability values and utility values associated 
with each of the disorders included in the cost-effectiveness analysis.  The structure of 
the Markov model that was used for the cost-effectiveness analysis is also included in this 
section.   
3.1  SOURCES OF DATA 
As outlined in the review of literature, newborn screening has been studied by 
various researchers.  Decision analysis and modeling techniques using estimates from 
existing literature have been frequently used in these studies.    For the purpose of this 
study, data were required for incidence of disorders, cost of screening, costs of various 
sequelae, and probabilities of various sequelae.  Information on these variables was 
needed for each of the disorders included in the study.  The disorders included in this 
study (defined as post-expansion screening) were: Arginosuccinic Acidemia (ASA); 
Citrullinemia (CIT); Homocystinuria (HCY); Maple Syrup Urine Disease (MSUD); 
Glutaric Acidemia Type I (GA I);  Medium Chain Acyl CoA Dehydrogenase Disorder 
(MCADD) and other Fatty Acid Disorders; Tyrosinemia (TYR); and Classical organic 
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Acid Disorders (COAD) [including MMA (Methylmalonic academia), PA (Propionic 
Acidemia) and IVA (Isovaleric Acidemia)].  Since ASA and CIT were combined into one 
disorder category because of very similar clinical outcomes, the Markov model  included 
seven sub-trees representing each of the categories mentioned above.  Another sub-tree 
was used for representing the healthy child. 
3.1.1  Incidence 
Incidence data was obtained from the Texas DSHS (Department of State Health 
Services) case management division.  This division maintains an updated record of all 
newborns that test positive for any of the disorders screened by the newborn screening 
program.   
3.1.2  Costs 
Since this study was conducted from a payer’s perspective, only direct medical 
costs were included. These costs were obtained from DSHS, Baylor Institute of 
Metabolic Disease and from the literature as described below. 
3.1.2.1  Cost of Screening 
The State of Texas performs two screens on every newborn at the ages of 24-48 
hours and 7-14 days respectively.  Blood samples from infants who test positive after the 
second screen need to be sent for confirmatory testing.  The total cost of screening 
includes the cost of the first and second screens and the cost of confirmatory testing.  
Equipment costs were not included because the state public health laboratory rents the 
equipment from a company where it is required to pay only for the recurrent reagent 
costs.  The cost of reagent is reflected in the cost of screening. 
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3.1.2.2  Cost of Sequelae 
Within the scope of the current study, it seems logical to use actual cost data from 
Texas Medicaid to estimate the incidence of various disorders and for assessing the costs 
incurred for the treatment of positive cases.  However, after consulting with some of the 
experts in newborn screening, it became clear that estimating the cost of sequelae from 
Medicaid data may not be the best approach.  Experts also believe that for most disorders, 
the sequelae are too ambiguous to be accurately reflected in a single ICD-9 code.  
Further, the diagnosis may not be stratified by severity of the underlying condition (such 
as mild, moderate or severe).  For example, mental retardation can be a sequela for many 
of the metabolic disorders being studied.  A child suffering from mental retardation may 
need many services in addition to physician visits.  Medicaid data may not be the single 
best source for estimating all of these costs.  Further, children showing only mild 
symptoms of mental retardation may not be classified as mentally retarded and may 
utilize far fewer services than children with more severe forms of the condition.  
Therefore, although this study will specifically address the perspective of the State of 
Texas, cost data were estimated based on published studies and expert opinion. 
3.1.3  Probabilities of Sequeale 
It is important to have accurate estimates of the likelihood of various sequeale for 
conducting a rational cost-effectiveness analysis.  These probabilities were obtained from 
the literature and expert opinion. 
3.2  TARGET POPULATION  
The target population for this study is all infants born in the State of Texas since 
the expansion of the newborn screening program in 2007. Data for the year [2007] were 
used. 
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3.2.1  Inclusion and Exclusion Criteria  
The Markov model for cost-effectiveness analysis included a hypothetical cohort 
of infants born in Texas in 2007.  Published estimates of incidence data were used to 
assign probabilities for the occurrence of various disorders.  Actual incidence data 
(obtained from DSHS) was then compared with the expected incidence.  False positive 
rates were also obtained from historical data from DSHS.  False positive rates were 
necessary for allocating costs of confirmatory testing for all presumptive positive cases.   
For other cost estimates, studies published from1998-2008 were reviewed. 
3.3  THEORETICAL BASIS OF ECONOMIC EVALUATION OF HEALTH CARE 
Welfare analysis forms the core of most economic evaluations.  In social welfare, 
an individual is the basic unit of analysis and aggregates of individual economic activity 
constitute social welfare.  Each individual tries to maximize his/her utility where utility is 
defined as the satisfaction derived from a good or service.  Utilities of all individuals 
taken together constitute social welfare. Welfare analysis seeks to evaluate the economic 
impact of the various ways of allocating the available resources.  The goal of welfare 
analysis is to answer the following questions:76 
Is a certain resource allocation efficient? 
Who are the gainers and losers from this allocation?  What is the extent of their 
gains or losses? 
3.3.1  Paretian Welfare Economics 
Paretian welfare economics has two central concepts: Pareto improvement and 
Pareto efficiency.  A Pareto improvement is said to have occurred if a certain reallocation 
of resources leads to an increase in utilities of at least one individual.  If there are some 
                                               
76     Drummond M, Alistair M, eds. Economic Evaluation in Healthcare. Oxford: Oxford University Press; 
2001. 
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losers and some gainers, the outcomes of the reallocation process are said to be Pareto 
non-comparable because of the non-comparable nature of individual utilities.  Figure 3.1 
illustrates a hypothetical plot of the utilities of two individuals(U1 and U2).  If e is the 
starting point, then a reallocation that leads to y can be considered a Pareto improvement.  
Conversely, a change from e to w will be considered Pareto deterioration.  On the other 
hand, movement from e to x or e to z can neither be called an improvement, nor 
deterioration.  An extension of this idea can be that all points in quadrant B are Pareto 
superior to e while all points in quadrant C are Pareto inferior with respect to e.  
However, in quadrants A and D, one individual’s gain is another’s loss.  Therefore, all 
states in these two quadrants can be termed Pareto non-comparable.77 
Figure 3.1 Pareto Comparable and Pareto Non-comparable States 
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3.4  WILLINGNESS TO PAY  
Willingness to pay (WTP) or compensating variation (CV) is a way to establish 
preferences among options that are Pareto non-comparable.  WTP may be defined as the 
amount of money that an individual is willing to give up in order to attain a certain 
improvement in his/her health status.  According to this approach, monetary values are 
placed on Pareto non-comparable choices.  An aggregate of these monetary values can be 
translated into gain or loss in consumer welfare. Therefore, with CV, it would be possible 
to decide whether or not it was better for an individual to move from state e to x or state e 
to z (Fig. 3.1).  However, this generalization does suffer from the limitation that the value 
of $1 should be held constant for every individual.   
This reallocation of resources where monetary values are placed on different 
options is central to many health economic analyses such as the cost-benefit analysis 
(CBA).  Health economic analyses frequently use Quality Adjusted Life Years (QALYs) 
as a comparator across individuals.  As mentioned in Chapter 2, QALYs represent the 
quantity and the quality of life in a single unit.  For example, each year of life lived in 
perfect health is assigned a value of 1.0 while death is assigned a value of 0.  A disease 
state may be represented on this continuum by a value that is greater than 0 but less than 
1.0.78 
3.4.3  Cost-effectiveness Analysis 
If cost of treatment ‘a’ is Ca, cost of treatment b is Cb, effect of treatment a is Ea,  
and that of treatment b is Eb then cost-effectiveness can be represented as a ratio called 
the Incremental Cost Effectiveness Ratio (ICER)79: 
                                               
78     Bootman JL, Townsend RJ, McGhan WF. Principles of Pharmacoeconomics. Third ed. Cincinnati, 
OH: Harvey Whitney Books Company; 2005. 
79     Drummond M, Alistair M, eds. Economic Evaluation in Healthcare. Oxford: Oxford University Press; 
2001. 
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Ca – Cb 
ICER=   ----------- 
Ea  -  Eb 
This equation can be extrapolated to a population level where the cost of 
treatment A is μCA and the cost of treatment B is μCB.  Similarly expected population 
values of effects of treatments A and B can be represented by μEA and μEB.  Then 
various outcomes of incremental costs and effects may be summarized in the following 
four states80: 
1. μCA - μCB < 0; μEA - μEB > 0; an outcome where treatment A is both less 
expensive and more effective than treatment B (dominant). 
2. μCA - μCB > 0; μEA - μEB < 0; an outcome where treatment B is both less 
expensive and more effective that treatment A (dominant). 
3. μCA - μCB > 0; μEA - μEB > 0; an outcome that represents a trade-off such that 
treatment A is both more expensive and more effective than treatment B. 
4. μCA - μCB < 0; μEA - μEB < 0; an outcome that represents another trade-off 
situation where treatment B is both more expensive and more effective than 
treatment A.  
If the outcomes of two competing alternatives are to be compared in non-
monetary terms (such as health benefits), then QALYs are the preferred choice.  Decision 
makers seek strategies that maximize QALYs at the lowest cost. 
3.5  DECISION ANALYSIS 
Decision analysis is a formal methodology of analyzing the alternatives available 
to a decision maker.  As shown in fig. 3.2, each alternative is represented by a “branch” 
                                               
80     Ibid. 
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of a “tree.” Uncertainty associated with each alternative is represented by a probability 
value.  The final outcome of each alternative is calculated as a weighted measure of its 
value.  The weight is represented by the respective probability of that outcome.  Decision 
analysis is based on a set of basic rules81: 
a) The tree flows from left to right where the earliest events are listed at the extreme 
left and successive events are listed to the right. 
b) Events in the tree are represented by various nodes. Decision nodes (showing the 
available choices) are represented as squares; chance nodes (showing the likely 
outcomes) are represented by circles; and terminal nodes (showing the final 
outcome) are represented by triangles. 
c) Branches originating from the decision node should represent all the choices and 
each of those choices should be mutually exclusive. 
d) Branches originating from the chance node should represent the likely outcomes.  
Each of these outcomes should be mutually exclusive such that their probabilities 
sum to 1.0.   
e) Terminal nodes should represent the net “pay off” of various alternatives shown 
in the model. 
                                               
81     Sonnenberg M, Beck J. Markov models in medical decision making. Med Decis Making. 
1993;13:322-338. 
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Figure 3.2 Depiction of a Basic Decision Analysis Tree 
 







   Outcome 2 
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3.5.1  Basics of Markov Modeling  
Markov models are a popular method of estimating disease prognosis and life 
expectancy.  In its initial usage, researchers used matrix algebra to develop a fundamental 
model that estimated the length of time a patient might spend in a particular health state.  
Since then, Markov models have evolved substantially. Most present day researchers use 
sophisticated decision analytic software to construct and evaluate Markov models.  The 
following paragraphs discuss some of the key concepts in Markov modeling.82 
A Markov model is based on the assumption that a patient can be in one and only 
one health state at a given time.  This is called a Markov state.  Each Markov state has a 
specific utility value. The total time-frame included in a Markov analysis is divided into 
equal intervals.  Each interval represents a Markov cycle.  As one Markov cycle leads 
into the next cycle, it is possible for a patient to move to another health state or continue 
to stay in the same health state.  The utility attributed to a specific health state is called 
the Incremental Utility of that health state. The Expected Utility of the entire Markov 
process is an aggregate of incremental utilities of each of the health states multiplied by 
the length of time spent in that state.83   
n 
Expected Utility =      ∑ ts X Us 
s=1 
Where ts = time spent in a health state and Us = Utility of that health state 
For example, if a patient spends 3.5 years in the “Well” state and 2 years in the 
“Disabled” state and then enters the “Dead” state, the expected utility would be: 
Expected Utility = (3.5 X 1.0) + (2 X 0.6) = 4.7 QALY 
                                               
82     Ibid. 
83     Ibid. 
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Utility of “Well” state = 1.0 
Utility of “Disabled” state = 0.6 
This analysis can also be further expanded to include financial cost of being in each state 
for a given length of time. 
A transition probability is the likelihood that a patient may move from one health 
state to another.  Theoretically, a Markov process with “n” states may be represented by 
n2 transition probabilities.  However, in practice, the probability of “disallowed” 
transitions is zero.  For example, the probability that a patient will transition from “Dead” 
to “Well” or from “Dead” to “Disabled” is zero.  Each Markov process includes at least 
one permanent state; one from which a patient cannot transition into another state.  Such 
a Markov state is termed as an Absorbing state.  At the end of the Markov process, all the 
patients will end up in the absorbing state.  “Death” is an example of an absorbing state.  
In a Markov process, certain states may be such that a patient can stay in them for only a 
limited period of time (at the most one cycle).  Eventually the patient has to transition to 
another state.  These states are known as Temporary states and are frequently used to 
assign specific utility values and costs associated with a health state.  For example, if an 
infant suffers a metabolic crisis, he/she may transition to “Disabled” or “Dead” state.  It 
is not possible to stay in the “Metabolic Crisis” state for a very long time.  However, the 
use of this state may enable the researcher to allocate costs associated with such an event.  
Further, the probability of death for an infant who has suffered a metabolic crisis event 
may be different from the one without it.  Therefore, transition states help in making a 
Markov model more accurate and realistic.  Tunnel states are a series of temporary states 
that may be followed only in a certain sequence.  Just like the individual transition states, 
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tunnel states can also facilitate the assignment of transition probabilities and costs for 
special events.  In this case, however, the event may last longer than one Markov cycle.84  
3.6  COSTS INCLUDED  
The study included all direct medical costs incurred during the screening process 
as well during follow-up and treatment of positive cases.  Direct non-medical costs such 
as transportation and indirect or productivity costs such as wages lost by caregivers were 
not included because the study was conducted from a payer’s perspective. A base 
discount rate of 3% was used in all the calculations. 
3.6.1  Direct Medical Costs 
Direct medical costs related to newborn screening can vary depending on the 
underlying disease state and the severity of sequelae experienced by the patient.  For the 
purpose of this study the following cast categories were considered: 
1. Cost of screening 
2. Cost of confirmatory testing 
3. Cost of false positive results 
4. Cost of disease management such as cost of special diet, cost of medications, cost 
of emergency room visits, cost of inpatient stay etc. 
5. Cost of specific sequelae such as cost of mental retardation, cost of neurological 
damage, cost of developmental delay, cost of lens dislocation, cost of spinal 
osteoporosis, cost of chronic renal failure, cost of liver transplant etc.   
                                               
84     Ibid. 
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3.7  MODEL INPUTS 
The following tables (3.1 - 3.3) describe the model inputs for estimated costs, 
probability values and utility values.  Variable names, their short description, their base 
value, their high and low values (for sensitivity analysis), and source of data are included. 
Ranges of variables were based on a mix of clinical and economic information.  For 
probability estimates, overall life-time values are presented.  Details of yearly estimates 
of probability values (wherever applicable), of clinical outcomes in each disorder 
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3.8  MODEL ASSUMPTIONS 
The following assumptions were used while conducting the cost-effectiveness 
analysis.   
1. A child can have only one metabolic disorder. 
2. Testing is timely and testing methods are appropriate. 
3. MS/MS is used for screening for the disorders included in this study. 
4. In an individual experiencing more than one sequela, disutility caused by the most 
debilitating sequela also includes the disutility caused by other, less debilitating 
co-morbidities.   
5. Newborn screening in Texas is universal. 
6. The base case discount rate for costs and effectiveness (utilities) is 3%. 
3.9  CYCLE LENGTH AND TERMINATION CONDITION 
The cycle length was one year.  One year was deemed as an appropriate cycle 
length since most clinical data on health outcomes was available on a yearly basis.  Half 
cycle corrections were used for initial values of costs and utilities to avoid over 
estimation.  One-time costs incurred in the first year of life such as cost of screening and 
diagnostic testing were not subject to half cycle correction.  The Markov model 
terminated after 76 cycles which is equivalent to the estimate of average life expectancy. 
3.10  PROPOSED STRUCTURE OF MARKOV MODEL 
This section includes a description of the proposed decision tree for estimating the 
cost-effectiveness of the expanded newborn screening program. The model is designed to 
estimate the incremental cost and effectiveness of only those disorders that were included 
in the screening panel after its expansion in 2007.  Disorders that were already in the 
panel before the expansion are not included. The disorders included in the analysis were 
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grouped into seven categories based on their physiological characteristics.  As shown in 
figure 3.3, the decision node for newborn screening has two main branches, one each for 
the expanded and the unexpanded screening programs.  The branch representing the 
expanded program further has eight sub-branches arising from a chance node.   Seven of 
the sub-branches represent the outcomes for the disorders being studied and the eighth 
branch represents outcomes for the healthy child. An infant can either be affected with 
one of the screened disorders or be healthy.  A large majority of healthy infants should 
have a negative screen result while a small fraction may have a false positive screen 
result.  Since the sensitivity of screening via tandem mass spectrometry is close to 1.0, we 
can choose not to include a branch for false negative results.  The probability of testing 
positive for any one of the disorders is equal to the prevalence of that particular disorder.  
The sub-tree branches for unexpanded screening are identical to that for expanded 
screening.  However, patients in the unexpanded screening branch are likely to 
experience greater morbidity and mortality because of delayed treatment.  Hence, the 
probability values for each of the outcomes will be different for the expanded and 
unexpanded scenarios. 
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Note: # = probability of a negative result, which equals 1- (combined probability of all 
the other scenarios). 
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3.10.1 Disease Characteristics and Proposed Markov Structure 
The Markov sub-tree for each of the disorders is based on the evidence in the 
literature.  Overall, the literature for many of the disorders is sparse compared to that for 
some of the more common pediatric conditions.  Some of the older studies include case 
reports that describe the natural history and disease progression among a small patient 
group seen at a single clinic.  In the last few years, screening programs across the 
developed world have been expanded and there has been an increased interest in various 
aspects of screening.  This interest is reflected in the literature as well with an increase in 
the number of good quality studies published in the recent years.  The following sections 
describe the sequelae experienced by patients of inborn errors of metabolism.  The 
Markov structure of the sub-tree representing each disorder is also presented.  Expert 
opinion was sought whenever the information in the literature was insufficient. 
3.10.1.1  Arginosuccinic Acidemia (ASA) and                                               
Citrullinemia (CIT)166 167 
ASA and CIT are both disorders of the urea cycle characterized by an inability to 
convert ammonia into urea. Infants with ASA lack the enzyme argininosuccinic acid 
lyase.  This enzyme is responsisble for the breakdown of ammonia.  Affected infants may 
appear normal at birth.  However, due to a buildup of ammonia (hyperammonaemia), the 
affected child begins to experience developmental delay, mental retardation and 
neurological damage between the ages of 1-3 years.  CIT presents itself as either an acute 
neonatal form or as a milder, late-onset form.  Soon after birth, infants with the acute 
neonatal form suffer build-up of toxic substances such as ammonia and glutamine.  Such 
                                               
166     Scriver CR, ed. The metabolic & molecular bases of inherited disease. 8th ed. New York: McGraw 
Hill; 2001. 
167     Drummond-Borg M. Metabolic Consultant Physician, Texas Department of State Health Services. In: 
Tiwana S, ed. Austin; 2007. 
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accumulation can lead to vomiting, loss of consciousness and death in an untreated 
patient.  Even after timely intervention, prognosis for acute CIT is poor.  Significant 
neurocognitive deficiencies are frequently observed.  
Prior to the 1980s, patients of Urea Cycle Disorders such as ASA and CIT were 
treated with protein restriction alone.  For the last two decades, an extensive therapy that 
includes supplements of arginine/citrulline and essential amino acids along with sodium 
phenyl acetate and sodium benzoate has been used for treating these patients. Experts 
agree that although survival has improved for urea cycle patients, rates of mental 
retardation tend to remain high.   
Figure 3.4  represents the Markov states for ASA and CIT.  The probability values 
used in the Markov sub-tree representing outcomes for screened versus unscreened 
patients of ASA and CIT were based on expert opinion.168 Please note that the structure 
of the sub-tree is identical for screened and unscreened populations.  However, 
unscreened patients may have greater likelihood of adverse outcomes.  These differential 
probabilities will be included in the analysis. (Please refer to Tables 3.1 to 3.3 for 
variable description and model inputs.) 
                                               
168     Ibid. 
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Figure 3.4 Markov Sub-tree for Arginosuccinic Acidemia (ASA) and Citrullinemia 
(CIT).   
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3.10.1.2  Homocystinuria (HCY)169,170 
HCY is another enzyme deficiency disorder that may be grouped with other Urea 
Cycle Disorders.  Due to some unique sequelae of this particular disorder, it is being 
analyzed as a separate category.  It is characterized by the build up of the amino acid 
homocystine.  Patients may suffer mental retardation, lens abnormalities and skeletal 
abnormalities. Lens abnormalities can be corrected, so only occur in one cycle of the 
structure. Premature death may occur due to thromboembolism (blood clot formation).  
Treatment for HCY includes restricted diet, B6, B12 and Betaine supplementation and 
Cystine in some cases. 
Figure 3.5 represents the Markov states for HCY.  Please note that the structure of 
the Markov sub-tree is identical for screened and unscreened populations.  However, 
unscreened patients may have greater likelihood of adverse outcomes.  These differential 
probabilities were included in the analysis. (Please refer to Tables 3.1-3.3 for variable 
descriptions and model inputs.) 
                                               
169     Scriver CR, ed. The metabolic & molecular bases of inherited disease. 8th ed. New York: McGraw 
Hill; 2001. 
170     Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine 
beta-synthase deficiency. Am J Hum Genet. Jan 1985;37(1):1-31. 
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3.10.1.3  Maple Syrup Urine Disease (MSUD)171 
MSUD is characterized by enzyme deficiency in the metabolic pathway of 
branched-chain amino acids including leucine, isoleucine and valine.  The urine of 
affected infants have a distinct “maple syrup” odor.  Elevated blood levels of branched-
chain amino acids, especially leucine, are associated with “metabolic intoxication”.  
Neonates with classical MSUD begin to show signs of crisis within 48 hours of birth.  It 
is common to witness seizures and cerebral edema by the age of 4 days.  Coma and 
respiratory failure can occur within 7-10 days.  Long term outcomes include neurological 
disorders and developmental delay.  The gene responsible for MSUD is common in the 
Mennonite communities where incidence of this disorder may be as high as 1 in 200.  
Treatment includes special diet and thiamine supplements.  One of the most 
comprehensive studies on the outcomes of MSUD has been conducted at the Clinic for 
Special Children in Pennsylvania.  Study results were based on long-term follow up of 36 
patients most of whom were from the Mennonite settlements in Eastern Pennsylvania.  It 
was reported that significant morbidity may occur even in infants diagnosed within 6-10 
days of age.  A diagnosis after the age of 14 days results in severe morbidity and 
mortality.     
Although it is possible to clinically diagnose MSUD within few hours of birth, it 
is more likely for specialists attending high-incidence patient populations to be able to do 
so. In states like Texas where MSUD may occur in 1 out of 200,000 infants, newborn 
screening may play an important role in prompt and definitive diagnosis of this disorder.   
Figure 3.6 represents the Markov states for MSUD.  Please note that the structure 
of the Markov sub-tree is identical for screened and unscreened populations.  However, 
                                               
171     Morton DH, Strauss KA, Robinson DL, Puffenberger EG, Kelley RI. Diagnosis and treatment of 
maple syrup disease: a study of 36 patients. Pediatrics. Jun 2002;109(6):999-1008. 
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unscreened patients may have greater likelihood of adverse outcomes.  These differential 















Death due to Metabolic crisis
MSUD_Death_WithScr[_stage;P_Die_MSUD_WithScr]








Incr Eff : Discount(U_TX;dr;_stage)







Death due to metabolic crisis
MSUD_Death_WithScr[_stage;P_Die_MSUD_WithScr]








Incr Eff : Discount(U_MR_ND_DD;dr;_stage)







Death due to metabolic crisis
MSUD_Death_WithScr[_stage;P_Die_MSUD_WithScr]








Incr Eff : Discount(U_MR_ND_DD;dr;_stage)
Final Eff : 0







Incr Eff : 0






3.10.1.4  Tyrosinemia Type I (TYR)172 
Tyrosinemia type I is an autosomal disorder characterized by severe liver damage 
because of enzyme deficiency in the tyrosine metabolic pathway. If left untreated, 
survival among tyrosinemia patients is extremely poor.  Death occurs before the age of 
10 years due to liver failure or hepatic carcinoma. 
In 1991, 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) was 
used in a trial for treating tyrosinemia type I .  This new treatment proved effective in 
averting tyrosine degradation and the adverse outcomes associated with it.  Since then, 
the prognosis for tyrosinemia type I patients has improved dramatically.  In a 1998 study, 
outcomes of 176 patients treated with NTBC have been reported.  Patients who received 
treatment before the age of two years were considered “early treatment group (n=101)” 
and those who received treatment after the age of 2 years were considered “late treatment 
group (n=75).”  Overall, a total of 18 liver transplants were performed in the early 
treatment group.  The reasons for transplant included poor response to NTBC treatment, 
progressive liver disease with suspected hepatic carcinoma, end stage liver disease and 
elective transplant.  Of the 18 patients, 6 did not survive after the transplant. If patients 
receiving treatment before the age of six months are considered separately, then 10% of 
the patients in this group required liver transplants because of poor response to NTBC 
treatment.  Half of these transplant recipients died because of complications.  
In the late treatment group, many patients with a milder form of the disease were 
also included along with those who had severe complications.  Liver transplant was 
required in 13/75 patients.  Of those, 3 patients died due to complications related to the 
                                               
172     Holme E, Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-
cyclohexanedione). J Inherit Metab Dis. Aug 1998;21(5):507-517. 
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transplant.  Two other deaths were reported in the late treatment group because of other 
complications.   
It is important to note that even in the absence of universal screening for 
tyrosinemia, an effective treatment plan was available for this disease.  However, patients 
received this treatment only when they were diagnosed because of their clinical 
symptoms.  Depending upon the severity of their disease, patients may present clinical 
symptoms early in life or may remain asymptomatic until much later.   For the purpose of 
constructing a Markov sub-tree for tyrosinemia type I, it may be appropriate to use the 
combined data of both the late and early treated groups as an estimate of outcomes 
without universal screening.  With newborn screening, infants with a positive diagnosis 
of tyrosinemia will start treatment as early as the first month of life.  Therefore, study 
results for patients receiving treatment before the age of six months may be a reasonable 
estimate for patient outcomes in the presence of universal screening.  Please refer to 
Tables 3.1-3.3 for model inputs.  Figure 3.7  represents the Markov states for 
tyrosinemia. 
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3.10.1.5  MCADD and Other Fatty Acid Disorders173,174,175 
Infants diagnosed with MCADD are unable to metabolize fatty acids.  They 
primarily rely on carbohydrates for their energy needs.  Most MCADD patients are 
started off with no treatment.  A positive diagnosis of MCADD is followed by counseling 
of the parents.  Parents are made aware of the dangers of prolonged fasting (greater than a 
few hours) in MCADD patients.  They are also instructed to bring the child to the 
hospital if the child refuses to eat due to minor illness.  The sick child may be given 
intravenous fluids in the hospital.   
In a study of 59 children with MCADD, health care utilization and costs were 
compared between screened and unscreened groups.  While only about 15% of the 
screened patients used inpatient services, inpatient admissions were significantly higher 
in the unscreened group (p = 0.01).  This number was consistently higher for the 
unscreened groups.  However, the average number of inpatients stays was similar for the 
two groups (about 1 per year) and the length of stay was also similar (2.6 days).176  It has 
been reported in the literature that of the children who are hospitalized due to MCADD- 
related complications, one third may develop some type of developmental delay.  About a 
third of those may suffer serious complications.177  These estimates were used to 
construct the sub-tree for MCADD. In the absence of screening, about 25% of MCADD 
                                               
173     Haas M, Chaplin M, Joy P, Wiley V, Black C, Wilcken B. Healthcare use and costs of medium-chain 
acyl-CoA dehydrogenase deficiency in Australia: screening versus no screening. J Pediatr. Aug 
2007;151(2):121-126, 126 e121. 
174     Grosse SD, Khoury MJ, Greene CL, Crider KS, Pollitt RJ. The epidemiology of medium chain acyl-
CoA dehydrogenase deficiency: an update. Genet Med. Apr 2006;8(4):205-212. 
175     Hsu HW, Zytkovicz TH, Comeau AM, et al. Spectrum of medium-chain acyl-CoA dehydrogenase 
deficiency detected by newborn screening. Pediatrics. May 2008;121(5):e1108-1114. 
176     Haas M, Chaplin M, Joy P, Wiley V, Black C, Wilcken B. Healthcare use and costs of medium-chain 
acyl-CoA dehydrogenase deficiency in Australia: screening versus no screening. J Pediatr. Aug 
2007;151(2):121-126, 126 e121. 
177     Grosse SD, Khoury MJ, Greene CL, Crider KS, Pollitt RJ. The epidemiology of medium chain acyl-
CoA dehydrogenase deficiency: an update. Genet Med. Apr 2006;8(4):205-212. 
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patients would die.  Deaths can occur even in the screened population, primarily due to 
lack of adherence to treatment regimen (avoidance of prolonged fasting).  In a recent 
article, 2 deaths were reported among 47 infants screened for MCADD, 1/47 had a severe 
episode of metabolic crisis and 2/47 had neonatal hypoglycemia.178 Please refer to Tables 
3.1-3.3 for model inputs.  Figure 3.8 represents the Markov sub-tree for MCADD and 
other fatty acid disorders. 
 
                                               
178     Hsu HW, Zytkovicz TH, Comeau AM, et al. Spectrum of medium-chain acyl-CoA dehydrogenase 
deficiency detected by newborn screening. Pediatrics. May 2008;121(5):e1108-1114. 
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Figure 3.8 Markov Sub-tree for MCADD and Other Fatty Acid Disorders 
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3.10.1.6  Glutaric Acidemia Type I179 
GA I is a disorder of the metabolic pathway for the amino acids lysine, 
hydroxylysine and tryptophan.  The impact of a compromised metabolic pathway is 
compounded by a concurrent illness.  Affected infants may present with acute stroke-like 
brain damage (striatal necrosis) between 6-18 months of age with majority of cases 
presenting between 6-14 months.  The disease is also known as “Amish cerebral palsy” 
because of its high prevalence in this community of Lancaster County, Pennsylvania.  At 
the time of clinical diagnosis, most patients have suffered irreparable damage to their 
brain and may remain disabled for life.  In a study describing the natural history of 77 
patients seen at the Clinic for Special Children in Pennsylvania, Strauss et al. emphasized 
the importance of early diagnosis via screening.  They reported that timely intervention in 
asymptomatic GA I patients may reduce the occurrence of brain damage from as much as  
90% to 35%.180   These results have been used to allocate probabilities to the sequeale in 
the sub-tree for GA I.   
Figure 3.9 represents Markov states for GA I.  Please note that the structure of the 
Markov sub-trees is identical for screened and unscreened populations.  However, 
unscreened patients may have greater likelihood of adverse outcomes.  These differential 
probabilities will be included in the analysis. (Please refer to Tables 3.1-3.3 for model 
inputs.) 
                                               
179     Strauss KA, Puffenberger EG, Robinson DL, Morton DH. Type I glutaric aciduria, part 1: natural 
history of 77 patients. Am J Med Genet C Semin Med Genet. Aug 15 2003;121C(1):38-52. 
180     Ibid. 
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3.10.1.7  Classical Organic Acid Disorders (IVA, MMA, PA)181 
Classical organic acid disorders (COAD) are a group of three disorders namely 
isovaleric aciduria (IVA), propionic aciduria (PA) and methylmalonic aciduria (MMA).  
These disorders are characterized by an inability to metabolize one or more branched-
chain amino acids such as leucine, isoleucine, valine, methionine and threonine.  
Treatment includes a special diet. 
The Markov states for the affected infants are based on a 2006 study describing 
the long-term outcomes of classical organic acid disorders.  In this study, Dionici-Vici 
and colleagues compared the outcomes for patients detected via clinical symptoms with 
those detected via newborn screening.   
The clinical diagnosis group included 29 patients with either IVA or MMA or PA.  
The median age of diagnosis was 7 days of age.  More than half (51%) of these patients 
experienced early mortality.  Most of the deaths (40%) occurred before the age of 2 
years.  The survivors also experienced poor outcomes such as chronic renal failure 
(among those who had MMA), and neurocognitive impairment.  There were 12 patients 
who survived with MMA.  All of them experienced chronic renal failure after the age of 
6 years.  Progressive neurocognitive deterioration was observed in majority of the 
patients with all three disorders.  In the long run, only 27% of the survivors had normal 
neurocognitive outcome.  In order to accurately depict the prognosis for clinically 
diagnosed patients of classical organic acid disorders, a subset of these patients will be 
allocated to the Markov state of chronic renal failure along with neurological 
impairment.182    
                                               
181     Dionisi-Vici C, Deodato F, Roschinger W, Rhead W, Wilcken B. 'Classical' organic acidurias, 
propionic aciduria, methylmalonic aciduria and isovaleric aciduria: long-term outcome and effects of 
expanded newborn screening using tandem mass spectrometry. J Inherit Metab Dis. Apr-Jun 2006;29(2-
3):383-389. 
182     Ibid. 
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In the screened group (n=18), outcomes were better than the clinical diagnosis 
group.  The median age of diagnosis was 4 days.  There were two deaths (11%) and only 
one patient (5%) suffered chronic renal failure.  Neurological impairment was observed 
in 31% of the survivors (n=16).  Therefore, an estimated 27% of the total cohort (n=18) 
suffered neurological impairment. Please refer to Tables 3.1-3.3 for model inputs. Figure 
3.10 represents the Markov states for COAD.183 
Figure 3.10 Markov Sub-tree for Classical Organic Acid Disorders 
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3.11  DEALING WITH UNCERTAINTY – SENSITIVITY ANALYSIS 
It is common for decision models to include numerous parameters, each of which 
is estimated with certain inherent uncertainty.  Sensitivity analyses must be conducted to 
account for the uncertainty in estimation.  Results of a sensitivity analysis help decision 
makers in evaluating the robustness of the study results across various parameters.   For 
large non-linear models such as the one being used in the current study, a standard 
sensitivity analysis is difficult to manage and may also introduce bias in estimation.  
Therefore a probabilistic sensitivity analysis using Monte Carlo simulation was used to 
account for uncertainty in the model parameters.   
For most of the probability values used in the model, only point estimates were 
available from the literature.  A clinically meaningful range was constructed around this 
point estimate.  With the availability of only a mid point around which a high and low 
value was estimated, triangular distributions were assumed to be most suitable for 
representing uncertainty.  Although it can be argued that some health states are worse 
than death and therefore should be given a negative value, this practice is rarely followed 
in cost-effectiveness analyses.  The utility values used in this study were between 0 and 
1.0, where 0 represented death and 1.0 represented perfect health.   
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Chapter Four - Results 
This chapter includes the results for each of the study objectives.  Data on Texas 
newborns, incidence of newly included disorders in the screening panel, cost of screening 
and confirmatory testing, cost of treatment and follow-up and detailed results of cost-
effectiveness analysis (including one-way and probabilistic sensitivity analysis) are 
provided in this chapter. 
4.1  RESULTS FOR OBJECTIVE 1 
Demographic Characteristics of the Infant Population Served by the Texas 
Newborn Screening Program  
The latest birth data for Texas newborns was available for 2005.  Table 4.1 shows 
the most recent birth data (from 2005) divided by race and ethnicity for Texas newborns.  
Corresponding data for the United States births for the same year are also shown.  The 
2005 birth cohort for Texas was predominantly white (84.8%), followed by African 
Americans, Asian and Pacific Islanders and Native Americans.  The US Census also 
recommends that demographic data should be based on at least two ethnicities: Hispanic 
and Non-Hispanic.  Hispanics may belong to any race.  Overall, the number of Hispanic 
births in Texas (49.5%) was nearly equal to that of the Non-Hispanic births (50.3%).  










































































































































































































































4.2  RESULTS FOR OBJECTIVE 2 
 Incidence of Various Metabolic Disorders in Texas 
The incidence data of various disorders was available for 2007 and is shown in 
Table 4.2.  The 2007 incidence for ASA and CIT, HCY, MSUD, TYR and GA I was less 
than the incidence reported in the literature.  Incidence of MCADD and other fatty acid 
disorders, and COAD was higher than the expected number.  Estimated incidence was 
calculated for a birth cohort of 400,000 births in 2007.  No cases were found for 
Tyrosinemia.  With an incidence of 1/100,000 we were expecting that at least one case 
would have been diagnosed via newborn screening in Texas.  In the absence of any 
reported cases of TYR in Texas for 2007, national incidence was used in calculations of 






































































































































































































































































































































































































4.3  RESULTS FOR OBJECTIVE 3 
Cost of Screening and Confirmatory Testing 
The cost of screening was $29.50 per screen, yielding a cost of $59.00 per infant 
for two screens that are conducted in the state of Texas.  The cost of confirmatory testing 
(for infants who receive a positive screen result) varies by disorders.  Confirmatory 
testing cost for some disorders like MCADD and other fatty acid disorders is much more 
expensive than that for others.  This variation in cost is because of the nature of testing 
required to reach a confirmed diagnosis for a positive newborn screen.  Table 4.3 shows 
the list of confirmatory tests conducted for each condition along with the average cost.184  
The number of false positives and cost of confirmatory testing for false positives is also 
shown.  The overall cost of confirmatory testing for false positives was the highest for 
MCADD and other fatty acid disorders because of the high cost of testing and the high 
number of false positive newborn screen results.   
 
 
                                               
































































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   







































































































































































































































































































































































































































































































































































4.4  RESULTS FOR OBJECTIVE 4 
Average Direct Medical Costs of Screening and Follow-up 
Table 4.4 includes the average costs, average QALYs and ICERs for each of the 
disorder categories with or without screening at 0%, 3% and 5% discount rate. We had 
hypothesized that the average direct medical costs associated with treatment and follow-
up of patients in the screening (expanded screening) category will exceed the average 
direct medical costs for those in the without screening (pre-expansion) strategy.  As 
shown in table 4.4, costs associated with expanded screening strategy exceed those 
associated with pre-expansion strategy,  except in case of HCY.  So hypotheses H4.1, 
H4.3 – H4.7 are accepted and hypothesis H4.2 is rejected. 
4.5  RESULTS FOR OBJECTIVE 5 
Average QALYs. 
Table 4.4 includes the average costs, average QALYs and ICERs for each of the 
disorder categories with or without screening at 0%, 3% and 5% discount rate. We had 
hypothesized that the average QALYs for patients in the screening category will exceed 
the average direct QALYs for those in the pre-expansion strategy. Table 4.4 supports 
these hypotheses.  So hypotheses Ho5 A1 – Ho5 A7 are accepted. 
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CIT 0% $1,858,587.90 33.78 $1,455,540.31 26.33 54,100.35 
 3% $767,266.22 14.02 $605,811.70 11.03 53,998.17 
 5% $520,300.84 9.55 $413,476.69 7.56 53,680.48 
       
HCY 0% $711,471.80 59.74 $837,816.55 45.44 Dominant 
 3% $286,263.31 24.08 $335,448.14 18.53 Dominant 
 5% $190,269.96 16.03 $222,290.79 12.43 Dominant 
       
MSUD 0% $376,141.93 61.34 $89,994.38 13.74 6,011.50 
 3% $150,910.26 24.70 $37,439.39 5.74 5,984.75 
 5% $100,092.02 16.42 $25,587.85 3.93 5,965.10 
       
TYR 0% $891,069.00 67.19 $214,050.25 16.27 13,295.73 
 3% $363,787.77 27.70 $86,440.83 6.70 13,206.99 
 5% $244,856.90 18.78 $57,657.12 4.54 13,146.05 
       
MCADDD 0% $411,262.22 46.94 $351,892.31 35.31 5,104.90 
 3% $158,373.64 20.36 $143,077.69 15.25 2,993.33 
 5% $102,668.00 14.09 $96,268.78 10.61 1,840.98 
       
GA I 0% $675,749.24 57.65 $76,787.93 3.92 11,147.61 
 3% $374,870.87 23.30 $67,487.43 3.56 15,571.60 
 5% $306,724.33 15.55 $62,274.50 3.35 20,036.87 
       
COAD 0% $505,306.60 55.68 $380,682.52 34.92 6,003.09 
 3% $200,339.86 22.74 $149,897.00 14.54  6,151.57 
 5% $131,797.86 15.27 $98,237.95 9.91 6,261.18 
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4.6  RESULTS FOR OBJECTIVE 6 
ICERs for Each Disorder Category and Results of the Cost-effectiveness of 
Expanded Newborn Screening Using MS/MS as Compared to Unexpanded 
Screening Using a Cost-utility Analysis (CUA) 
The ICER for all disorder categories was less than the Rc of $50,000, except in 
case of ASA and CIT where it exceeded the Rc (Table 4.4).  Therefore H6.1 is rejected 
and H6.2-H6.7 are accepted.   
As shown in Table 4.5, the ICER for expanded screening versus pre-expansion 
screening  was $12,347.89/QALY at the base discount rate of 3%.  At the base case 
estimate, expanded screening costs an additional $40.90 and results in an additional 
0.00331 QALYs.   
Tables 4.6 and 4.7 show the results of the cost-effectiveness analyses at 0% and 
5% respectively.    Therefore, expanded screening was cost effective as compared to pre-
expansion screening.    



















Screening $103.30    30.69632    $3.37    
Expanded 
Screening $144.20  $40.90  30.69963 0.00331  $4.70  $12,347.89  
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Screening $163.30    75.9858    $2.15    
Expanded 
Screening $257.90  $94.50  75.9941  0.0083  $3.39  $11,419.31  
 


















Screening $89.70    20.48140   $4.38    
Expanded 
Screening $118.70  $29.00  20.48358  0.00218  $5.79  $13,312.50  
4.7  RESULTS OF ONE-WAY SENSITIVITY ANALYSES TORNADO DIAGRAMS 
This section describes the results of one way sensitivity analyses performed on the 
study variables.  A preliminary sensitivity analysis using a tornado diagram was 
performed for each of the variable categories (costs, probabilities and utilities).  Another 
sensitivity analysis was performed just for discount rate since this variable did not belong 
to any of the above mentioned categories.  A final tornado diagram was created with the 
top few most influential variables from each category.   
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As shown in Fig 4.1, the ICER for expanded screening varies between 
$11,418/QALY and $13,311/QALY with variations in the discount rate from 0% to 5%.  
Within the cost category, the most influential cost variables were yearly cost of 
medications for Tyrosinemia, yearly cost of special diet, yearly cost of carnitine 
supplementation, yearly cost of neurological damage and the yearly cost of medication 
for ASA and CIT (Figure 4.2).  Within the probability category, probabilities of death 
due to ASA and CIT with and without screening were among the most influential 
variables.  Probability of neurological damage due to GA I with and without screening, 
and probability of being clinically diagnosed with tyrosinemia were other important 
variables (Figure 4.3).  Within the utility category, the utility value of being on restricted 
diet was the most influential variable followed by the utility value of mental retardation, 
neurological damage and developmental delay, and utility value of having chronic renal 
failure respectively (Figure 4.4). 
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Figure 4.5 shows the impact of the top few variables from each category on the results of 
the cost-effectiveness analysis. Yearly cost of medications for Tyrosinemia was the most 
influential variable, followed by the utility of treatment without complications.  Other important 
variables were yearly cost of special diet, probability of death with and without screening in 














































4.8  RESULTS OF PROBABILISTIC SENSITIVITY ANALYSIS 
Figure 4.6 shows the cost-effectiveness scatterplot obtained with a probabilistic 
sensitivity analysis.  The mean value of cost for expanded screening was $169 (SD $28.87; range 
$120-$285).  The mean effectiveness for expanded screening was 35.224 QALYs (SD 9.971 
QALYs; range 20.568-74.451 QALYs).  For pre-expansion screening, mean cost was $146 (SD 
$23.20; Range $107 - $239).  The mean effectiveness for pre-expansion screening was 35.222 
QALYs (SD 9.970 QALYs; Range 20.567 – 70.446 QALYs).  A majority of the data points 
(97.5%) for expanded screening are at or below a cost of $244 and effectiveness of 61.098 
QALYs.  For pre expansion screening, 97.5% of the data points are at or below a cost of $206 
and effectiveness of 61.094 QALYs.  Therefore, on an average, expanded screening was 
associated with higher costs and slightly higher QALYs. 
Figure 4.6 Cost-effectiveness Scatterplot Obtained from Monte Carlo Simulation 
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Figure 4.7 shows the acceptability curve for a willingness-to-pay threshold of $50,000 
per QALY.  Data points from the acceptability curve are presented in Table 4.8.  These results 
show that  at a WTP of $13,000/QALY, expanded screening (as compared to pre-expansion 
screening) is cost-effective  for 100% of the iterations of the probabilistic sensitivity analysis.  
On the other hand, if the WTP is only $9,000/QALY, pre-expansion screening is cost-effective 
for 100% of the iterations (as compared to expanded screening).  In other words, if a payer is 
willing to pay at least $13,000/QALY, then he/she would always choose expanded screening for 
any of the ranges used in our sensitivity analyses.  Conversely, if the payer is only willing to pay 
up to $9,000/QALY then he/she would choose the pre-expansion screening for any of these 























Figure 4.7 Acceptability Curve Obtained from Monte Carlo Simulation 
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Table 4.8 Acceptability Curve: Proportion Cost-effective for Each Screening Strategy 
Willingness 
to Pay  
Proportion Cost-effective 
for Expanded Screening 
Proportion Cost-effective for  
Pre-expansion Screening 
$9,000 0 1 
$9,500 0.1 0.9 
$10,000 0.2 0.8 
$10,500 0.3 0.7 
$11,000 0.5 0.5 
$11,500 0.7 0.3 
$12,000 0.8 0.2 
$12,500 0.9 0.1 
$13,000 1 0 
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Table 4.9 shows a summary of all the hypotheses that were tested in this study.  
Hypothesis H4.2 was rejected because based on our estimates, direct medical costs associated 
with screening of HCY were lower than the direct medical costs associated with no screening.  
Hypothesis H6.11 was also rejected because the ICER of expanded screening for ASA and CIT 
($53,998.17/QALY) was slightly higher than the Rc of $50,000/QALY.  All other hypotheses 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter Five - Discussion 
This chapter is aimed at providing a discussion of the study results and possible 
explanations for the findings.  Limitations of the current study and potential topics for 
future research are also discussed here.   
5.1  DEMOGRAPHIC CHARACTERISTICS OF THE INFANT POPULATION                SERVED BY 
THE TEXAS NEWBORN SCREENING PROGRAM 
Texas accounts for nearly 8% of the total US population.  With a 12% increase in 
population from 2000 to 2006, it is also one of the fastest growing states.  The National 
Newborn Screening and Genetic Resource Center (NNSGRC) maintains a record of birth 
data by race and ethnicity for each of the states.  The latest data available is for 2005.  For 
Texas, the number of births when categorized by ethnicity, are nearly equally divided 
between Hispanics and non-Hispanics.  However, the racial classification of the 2005 
Texas birth data shows that nearly 85% of the newborns were white.  This implies that 
infants classified as White could be of either Hispanic or non-Hispanic ethnicity.  
Further, those classified as Hispanic may belong to any race.  Although the NNSGRC 
data follows the same classifications as that of the US Census, birth certificate data is 
obtained by self reports from the infant’s family.  It is common to encounter 
inconsistencies between these two sets of data. As seen in border states like Texas, 
“Hispanic” may also be used as a race and not as an ethnicity.  Such discrepancies make 
it problematic to reliably allocate the birth data to discrete racial or ethnic categories.   
Study results do reflect that the percentage of Hispanic births in Texas is nearly twice that 
of the national average which may be attributed to the large population of individuals of 
Hispanic origin in the state.  These numbers may be comparable with the demographic 
distribution of other states like California that share similar characteristics with Texas.  
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However, the results cannot be generalized to many other states in the country where the 
Hispanic population is small.  
5.2  INCIDENCE OF VARIOUS DISORDERS IN 2007 (AFTER THE EXPANSION OF THE 
SCREENING PROGRAM)  
The disorder group with the highest incidence in 2007 was MCADDD and other 
fatty acids.  With 30 diagnosed cases, the combined incidence of this group of disorders 
is estimated at 1 in 13,300 in Texas. Incidence for MCADDD alone was at 1 in 20,000 
which is slightly lower than the national average of 1 in 17,000 reported by Grosse et al. 
in 2006.186  Other disorders were less prevalent with 0-7 cases detected in 2007.  The 
incidence of most disorders is a little higher or lower than the published numbers.    There 
were no cases reported for Tyrosinemia in 2007 which does seem somewhat unexpected.  
With an incidence of 1 in 100,000, we were expecting that at least one case of 
Tyrosinemia would have been detected by newborn screening.  Absence of any new cases 
of Tyrosinemia in the 2007 birth cohort could be a chance occurrence or could also be 
because of false negative screen results.  Incidence of all disorders may fall closer to 
published estimates over the long term.  Since none of the disorders being studied are 
thought to occur more frequently in either gender, the observed disparities in occurrence 
by gender (for 2007 data) may also become smaller over the long term. 
5.3  COST OF SCREENING AND CONFIRMATORY TESTING   
The cost of screening in Texas is lower than that in many other states. This 
difference is largely due to variations in allocation of federal funding for running state 
programs like newborn screening.  Cost estimates for confirmatory testing were obtained 
from the Institute of Metabolic Disease at the Baylor University Medical Center in 
                                               
186 {Grosse, 2006 #120} 
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Dallas, Texas.  The average cost of confirmatory testing was estimated at $1,000.  The 
Schoen study also used an estimate of $1,000 for the cost of false positive screen results 
for most of the disorder categories.  However, they only allocated $200 for a false 
positive screen for MCADDD.187  Our study results show that confirmatory testing for 
MCADDD and other fatty acid disorders is actually much more expensive 
(approximately $4,000 per case) than that for some of the other conditions.  Detailed 
genetic analysis for identifying specific gene mutations contribute to the higher cost. 
5.4  AVERAGE COST OF FOLLOW-UP AND TREATMENT FOR EACH DISORDER:     
For most of the disorders, expanded screening is associated with higher treatment 
and follow-up costs.  This can be explained by the increased life expectancy of patients 
detected early because of screening.  Once they are diagnosed for a certain condition, 
patients need to be on special diet and other treatment for the rest of their lives.  Early 
death may frequently be an outcome for unscreened patients.  Since the current study 
included only direct medical costs, there are no costs associated with loss of productivity 
due to mortality.  As a result, life-time costs for screened patients tend to be higher than 
those diagnosed post-symptomatically.   
5.5  AVERAGE QALYS 
The average quality adjusted life years (QALYs) for the screened groups are 
higher than those for the unscreened group.  Screening typically leads to earlier diagnosis 
and treatment.  With timely diagnosis and careful disease management, it is now possible 
for patients with metabolic disorders to lead relatively healthy lives.  Conversely, patients 
diagnosed post-symptomatically (in the unscreened population) may have a higher risk of 
mortality and poorer disease prognosis, which contribute to fewer QALYs.   
                                               
187 {Schoen, 2002 #19} 
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5.6  COST-EFFECTIVENESS OF EXPANDED NEWBORN SCREENING 
As shown by the results of CUA analysis, expanded screening may cost an 
additional amount of $12,000/QALY at the base discount rate of 3%.  Although the 
absolute difference in the effectiveness of the two strategies in relatively small at 0.00331 
QALYs, it can potentially make a significant difference for the infants detected with one 
of the disorders.  The ICER of expanded versus pre-expansion screening was compared 
with the commonly used threshold of $50,000/QALY.  It may be argued that the 
threshold of $50,000 may not be representative of the very specific costs and outcomes 
related to disease states.  Depending upon the nature of the health condition being 
studied, this value may be too high or too low.  Further, it may be more practical to use a 
range for an acceptable value of ICER instead of an absolute value of $50,000/QALY.  
Use of a range of acceptable ICER values allows for the inclusion of other factors like 
burden of disease and imprecise estimation of costs and QALYs.  The use of disease 
specific ICERs may be more feasible for conditions that have been studied extensively.  
Economic analyses of newborn screening are still relatively rare and a threshold ICER for 
this group of diseases may become clearer in the future.  
For ASA and CIT, screening costs an additional $53,998/QALY at the base rate 
of 3%.  This is higher than the WTP of $50,000 per QALY.  One of the factors 
responsible for the relatively higher cost/QALY for ASA and CIT is the very high cost of 
treatment for these disorders.  As per expert opinion, although screening results in higher 
survival among ASA and CIT patients, rates of mental retardation tend to remain high 
among the survivors.  Therefore, quality of life for the survivors is poor overall.    For 
HCY, screening not only costs less, but it also results in greater QALYs.  Therefore, it is 
the dominant strategy for HCY.  These results may be explained by the reduced 
likelihood of adverse outcomes in the screened group.  A vast majority of the unscreened 
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patients of HCY are at risk of lens dislocation and chronic skeletal abnormalities as they 
grow older.  These complications can result in significant direct medical costs and 
reduced quality of life.  In contrast, only a few of the screened patients run the risk of lens 
dislocation or spinal osteoporosis, thereby resulting in reduced costs and better quality of 
life.  For MSUD, there is a stark contrast in the QALYs for screened versus unscreened 
patients.  This can be explained by the extremely high mortality in the first two years of 
life for children who may be diagnosed late.  As a result, the quality of life for the dead 
members of the unscreened group is zero.  This contributes to the overall low QALYs in 
the unscreened group.  Yet, the ICER for screening versus no screening for MSUD 
($5,900/QALY) is well below the common threshold of $50,000/QALY. 
After HCY, MCADD is the second most cost-effective condition to screen for.  
Relatively low treatment costs and high prevalence of this disorder contribute to the 
economic viability of screening for this disorder.  The ICER of $2,993/QALY is lower 
than some of the published estimates.  Possible reasons for this difference could be the 
use of different model inputs. 
For MSUD, Tyrosinemia and GA I, the difference between QALYs for the 
screened and unscreened groups is large.  Screening for each of these conditions is cost-
effective with ICERs ranging from $5,900 to $15,500/QALY.  
Screening for COAD is also cost-effective with the ICER for screened group at 
$6,151/QALY.  Timely intervention is crucial in this group of disorders and patients can 
enjoy good quality of life without incurring extremely high treatment costs. 
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5.7  COMPARISON WITH OTHER STUDIES 
Table 5.1 Summary of recent economic analyses of newborn screening in North America 
Year 
(Section) 
Author(s) Type of 
Analysis 








CUA MSUD, MCADD, Glutaric 
Aciduria, MMA, PPA, Urea 
cycle disorders, 
Homocystinurea 
MS/MS yields an ICER 






CUA MCADD and other fatty acid 
disorders 








CEA/CUA MCADD MS/MS screening for 
MCADD requires an 
additional $5,600/QALY 
($11,000/LY) as 
compared to no 
screening.  Costs offset 






CUA PKU, CAH, CH, MSUD, 
Galactosemia, Homocystinuria, 
MCADD, biotinidase deficiency 
Multi-test screening is 
dominant approach in all 











Several MS/MS screening saves 
$1.5 million annually.  
Screening is the 
dominant strategy in 





Li et al.193 
CEA/CUA MCADD Screening for MCADD 
with MS/MS is cost-
effective based on a 
threshold value of 
$20,000 per QALY 
                                               
188     Schoen EJ, Baker JC, Colby CJ, To TT. Cost-benefit analysis of universal tandem mass spectrometry 
for newborn screening. Pediatrics. Oct 2002;110(4):781-786. 
189     Insinga RP, Laessig RH, Hoffman GL. Newborn screening with tandem mass spectrometry: 
examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. J Pediatr. Oct 
2002;141(4):524-531. 
190     Venditti LN, Venditti CP, Berry GT, et al. Newborn screening by tandem mass spectrometry for 
medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics. Nov 
2003;112(5):1005-1015. 
191     Carroll AE, Downs SM. Comprehensive cost-utility analysis of newborn screening strategies. 
Ibid.May 2006;117(5 Pt 2):S287-295. 
192     Feuchtbaum L, Cunningham G. Economic evaluation of tandem mass spectrometry screening in 
California. Ibid.:S280-286. 
193     Tran K, Banerjee S, Li H, Noorani HZ, Mensinkai S, Dooley K. Clinical efficacy and cost-
effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem 







CEA Several  Average cost of 
screening for PKU, along 
with 14 other disorders is 




Tiwana CUA ASA and CIT, HCY, MSUD, 
Fatty Acid Disorders, 
tyrosinemia, GA I, Classical 
Organic Acid Disorders 
Expanded screening with 




Results of the overall cost-effectiveness analysis are comparable with the results 
of other studies done in the past (Table 5.1).  However, there are differences in the 
disease states included in these analyses.  Other differences include varying costs and 
effectiveness estimates.  For example, the base-case results of the current study show that 
the ICER for expanded screening was approximately $12,000/QALY (2007 dollars) at a 
discount rate of 3%.  In their 2002 study, Schoen and colleagues reported their base-case 
estimate as $5,827/QALY (2002 dollars).195  Their results were based on estimates of a 
number of disease states, including PKU.  While the current study includes cost-
effectiveness estimates of screening for 6 of the 7 disorder categories used by Schoen et 
al., it does not include cost and effectiveness analyses for PKU.  Inclusion of PKU may 
have changed the results of the study since it is a much more prevalent condition as 
compared to many other disorders.  The Schoen study also estimated that the treatment 
cost for MCADD is zero while in the current study, we included the cost of carnitine 
supplementation ($4,000 to $6,000 per year) as a treatment cost for those MCADD 
patients who had experienced one or more episodes of hypoglycemia. 
In the Insinga study, it was reported that screening for MCADD and other fatty 
acids via tandem mass spectrometry (MS/MS) resulted in an ICER of $6,008/QALY.  
                                               
194     Cipriano LE, Rupar CA, Zaric GS. The cost-effectiveness of expanding newborn screening for up to 
21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. 
Value in Health. Mar-Apr 2007;10(2):83-97. 
195     Schoen EJ, Baker JC, Colby CJ, To TT. Cost-benefit analysis of universal tandem mass spectrometry 
for newborn screening. Pediatrics. Oct 2002;110(4):781-786. 
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They also included initial capital investment costs related to MS/MS.  These costs were 
not included in the current study.  Further, screening for multiple disorders may be more 
cost-effective as compared to screening for individual disorders.196 
Study results are also comparable to the findings of Venditti et al. (2003) where 
the cost of screening for MCADD was estimated at $5,600/QALY (2001 US Dollars).197   
The ICER for MCADD screening as compared to no screening was estimated at 
approximately $3,000/QALY in our study at a discount rate of 3%.  Although MCADD is 
deemed cost-effective by both the studies, there are some key differences in the costs 
included in the Venditti study and the current study.  Our study includes only direct 
medical costs where as the Venditti study included a societal perspective which would 
also include indirect costs due to productivity losses. The base-case estimate for the 
annual cost of carnitine supplementation is also assumed to be zero for the screened 
patients.  This again is divergent from the estimates used in the current study where a 
base-case estimate of $5,000 per year was used for carnitine supplementation for 
MCADD patients.  The risk of mortality in the unscreened patients diagnosed clinically 
was also much higher (40% or higher) than the estimates we used (25%).   
The Carroll and Downs study also compared a multi-test screening program with 
a “no screen” strategy and reported that screening was the dominant strategy for all 
disorders except congenital adrenal hyperplasia and galactosemia.198  Most of the 
conditions included in their analysis were already being screened for during the pre-
                                               
196     Insinga RP, Laessig RH, Hoffman GL. Newborn screening with tandem mass spectrometry: 
examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. J Pediatr. Oct 
2002;141(4):524-531. 
197     Venditti LN, Venditti CP, Berry GT, et al. Newborn screening by tandem mass spectrometry for 
medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics. Nov 
2003;112(5):1005-1015. 
198     Carroll AE, Downs SM. Comprehensive cost-utility analysis of newborn screening strategies. 
Ibid.May 2006;117(5 Pt 2):S287-295. 
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expansion screening program in Texas.  The current study includes only the newly added 
disorders to the screening panel.  Of those, MSUD, MCADDD and HCY were also 
studied by Carroll and Downs.  However, our study results show that screening for HCY 
is dominant while screening for the remaining disorder categories is cost-effective as 
compared to no screening.  The Carroll and Downs study also utilized a multiplicative 
utility model where individual values of disutility were multiplied to account for multiple 
sequelae suffered by the same patient.  In the present study, we used the utility value of 
the most debilitating condition versus using a product of individual utility values. For 
example, for a mentally retarded child on special diet, the utility value of mental 
retardation was used and not that of being on special diet.  Carroll and Downs also used 
separate utility estimates for mild, moderate and severe cases of each disorder.  Only 
average utility values were used in the current analysis. 
The current study results of $12,000/QALY are also higher than the cost-
effectiveness estimate provided by Feuchtbaum and Cunningham.199 According to their 
estimates, screening cost $1,628/QALY (2006 US dollars) in the base-case estimate.  
Instead of allocating separate costs to each of the disease sequelae, they had used an 
average estimate of $1 million for the cost of life time treatment and follow-up.  Their 
estimate was derived from a CDC report published in 2003.  However, the report 
elaborates that most of the costs in this $1 million estimate were based on the 
productivity loss due to lost wages and early mortality.200  The current study does not 
include productivity losses incurred either by the parents or by the patients (after they 
                                               
199     Feuchtbaum L, Cunningham G. Economic evaluation of tandem mass spectrometry screening in 
California. Ibid.:S280-286. 
200     Honeycutt A, Grosse S, Dunlap L, et al. Economic costs of mental retardation, cerebral palsy, hearing 
loss, and vision impairment. Research in Social Science and Disability. 2003;3:207-228. 
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reach adulthood).  If indirect costs were included in the present study, the results may be 
more comparable to the conclusions of Feuchtbaum and Cunningham.  
Results of the current study  show that screening for MCADD is cost-effective.  
This is in agreement with the findings of the Tran study (2007) where MCADD screening 
with MS/MS was reported as cost-effective at a threshold of C$20,000/QALY 
(USD15,400; 2004 estimate).201  However, the estimates of mortality due to MCADD 
used in the Tran study were quite different from the ones used in our study.  The 
literature shows that the likelihood of mortality is very small if timely screening and 
treatment is provided for MCADD.  Therefore, we consider the the 6% probability for 
screened MCADD patients used by the Tran study to be an over estimation.  Mortality for 
unscreened MCADD patients in the current study has been estimated at 20-25%.202  The 
Tran study used a probability of 8% for such patients which may be an under estimation.   
Study results also share some similarities with those of a recent study based on the 
cost-effectiveness of expanding newborn screening in Ontario Canada.  Cipriano et al. 
(2007) reported that if MS/MS is used for screening newborns for PKU along with other 
metabolic disorders, it would only be cost-effective to include PKU and 14 other 
conditions on a combined newborn screening panel.   Inclusion of MSUD, GA I, COAD 
and MCADD and other fatty acid disorders along with PKU would cost less than          
C$70,000 (USD 53,900; 2004 estimate) per life year gained.203 The Cipriano et al. study 
also reports that the addition of each of the remaining disorders (including Tyrosinemia, 
                                               
201     Tran K, Banerjee S, Li H, Noorani HZ, Mensinkai S, Dooley K. Clinical efficacy and cost-
effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem 
mass spectrometry. Clin Biochem. Feb 2007;40(3-4):235-241. 
202     Grosse SD, Khoury MJ, Greene CL, Crider KS, Pollitt RJ. The epidemiology of medium chain acyl-
CoA dehydrogenase deficiency: an update. Genet Med. Apr 2006;8(4):205-212. 
203     Cipriano LE, Rupar CA, Zaric GS. The cost-effectiveness of expanding newborn screening for up to 
21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. 
Value in Health. Mar-Apr 2007;10(2):83-97. 
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HCY, ASA, CIT and two other disorders) would cost at least $300,000 (USD 231,000; 
2004 estimate) per life year.  These results are somewhat divergent from our findings.  
Our results do show that the ICER of screening for ASA and CIT is above the threshold 
of $50,000/QALY.  However, our study found that screening for Tyrosinemia and HCY 
is cost-effective (dominant for HCY).  It is important to point out some key 
methodological differences between the Cipriano et al. study and the current study.  Their 
study was proposing the expansion of newborn screening in Ontario.  Therefore, they 
included the disorders in a step-wise manner where the decision to include each 
successive disorder in the panel could be based on incidence, prevalence and the 
availability of effective treatment.  While these are valid points to consider before any 
expansion of an existing program, they may not be useful for estimating the cost-
effectiveness of an expansion that has already taken place.  In our study, we looked at all 
the disorders simultaneously.  So the incremental costs and effectiveness compare the 
program before and after simultaneous expansion.  If Texas decided to undertake the 
inclusion of one or more disorders in the future, the approach used by Cipriano et al. may 
be helpful in the decision making process.  Another difference is the use of life years as 
the denominator in their cost-effectiveness analysis.  We used quality adjusted life years 
where the utility of being in each of the states was accounted for by using estimates 
available from the literature. 
5.8  RESULTS OF SENSITIVITY ANALYSES 
Results of the one-way sensitivity analyses point to several variables that may 
impact the results of the cost-effectiveness analysis.    The discount rate impacts all the 
costs and all the utilities as well; therefore, study results are sensitive to changes in the 
discount rate.   
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Cost of Tyrosinemia medications, cost of special diet and cost of carnitine 
supplementation were some of the most influential variables in the cost category.  Since 
the 1990s, all infants detected with Tyrosinemia are treated with expensive NTBC 
therapy.  Cost of this therapy can potentially impact the results of the cost-effectiveness 
analysis.  Every child who tests positive for any of the disorders is placed on a special 
diet.  Therefore, special diet cost has an impact on the entire cohort included in the 
analysis.  Cost of carnitine supplementation is also an important variable in the cost 
category.  Carnitine diet is recommended for all children who have complications related 
to MCADD.  Of all the disorders included in the study, MCADD and other fatty acid 
disorders is the most prevalent group of conditions and therefore cost of carnitine can 
affect a significant number of patients each year.  Cost of neurological damage can also 
have a widespread impact on the study results since it is a possible outcome for many 
disorders included in this study.  Some other variables such as the cost of liver transplant 
did not seem to influence the study results.  Although the cost of liver transplant is very 
high, it only impacts a very small proportion of the study cohort.   
Within the probability category, a significant decline in the probability of death is 
seen for the screened versus unscreened populations.  Further, a decline in mortality is the 
only major difference between the screened and the unscreened patients and other 
sequelae do not differ in spite of screening.  Patients who die due to ASA and CIT will 
not incur any direct medical costs, neither will they have any utilities (since the utility 
value of being dead is zero).  This may explain the influence of probability of death for 
ASA and CIT as an influential variable in this category.  Patients with GA I have a very 
high risk of neurological damage without screening and the risk still stays significant in 
the screened patients.  These patients would incur significant costs because of these 
outcomes which may explain why the probability of neurological damage in all cases of 
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GA I ranks as a significant variable.  The probability of being diagnosed with 
Tyrosinemia is directly related to the yearly treatment costs of these patients.  If more 
patients are diagnosed with Tyrosinemia, treatment costs would automatically go up 
For the category of utility values used in the Markov model, utility of being on 
treatment (with special diet) without any additional complications impacts most of the 
members of the cohort.  Therefore, it is not surprising that this variable shows as the most 
influential variable in the tornado diagram for the utility values.   
5.9  STUDY LIMITATIONS 
The main limitation of this study is that estimates from the literature were used 
instead of actual data for most of the costs, probabilities and outcomes.  Each of the 
published studies have their own inherent limitations and the screening program 
described in a study may be systematically different from the newborn screening program 
of Texas.  Many of the published results are also based on relatively short-term follow-
up.  For example, the hospitalization data for MCADD patients in Australia was only 
reported for the first four years of life.204  We estimated the likelihood of hospitalization 
for children older than 4 years of age.  Further, some of the studies have been conducted 
in specialty clinics or in high incidence communities.   Results from such studies may not 
be generalizable to other health care facilities or to communities where many of the 
disorders are extremely rare.  Expert opinion was used for some of the sequelae, where 
data from the literature were unclear or insufficient. There may be some subjectivity in 
expert opinion.     
                                               
204     Haas M, Chaplin M, Joy P, Wiley V, Black C, Wilcken B. Healthcare use and costs of medium-chain 
acyl-CoA dehydrogenase deficiency in Australia: screening versus no screening. J Pediatr. Aug 
2007;151(2):121-126, 126 e121. 
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Although sensitivity analyses showed that study results were robust to a wide 
range in variables, it is still important to recognize that the clinical data and the economic 
estimates included in this study came from different sources in the literature.  For 
example, clinical data for MSUD and GA I were obtained from studies conducted in 
Pennsylvania and cost estimates for many variables were obtained from studies 
conducted in California and Canada.  Data from such varied sources may not be 
generalizable to Texas.   
Based on the newborn screening program, specimens may be drawn from infants 
between 24-72 hours of birth.  Screening results are usually available 5-10 days from 
birth.  Some infants may die before any concrete diagnosis can be made.   
It is important to recognize that due to screening, milder forms of the disease may 
also be detected.  Due to the mild nature of the underlying disease, outcomes for these 
patients will be inherently better than those who have the severe form of the same 
disorder.  Inclusion of mildly affected patients in the cohort may create a positive bias in 
favor of screening.   On the other hand, when data on unscreened cohorts is used, it 
includes only the more severe cases since the mild forms of the disease may go 
undiagnosed.  Their disease prognosis is worse because of the severity of their disease 
which confounds the effect of late treatment (as compared to that of screened cohorts 
who are likely to receive early treatment).  
Another limitation was the lack of utility estimates specific to newborn screening 
disorders.  Although there is literature on conditions like mental retardation, neurological 
damage and renal failure, it is problematic to account for the disutility caused by 
individual sequelae when a patient is experiencing more than one complication.  Further, 
use of published estimates may not adequately reflect the disutility experienced by the 
pediatric patient.  There have been comparisons of the disutility caused by a false positive 
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newborn screen result with that of a false positive cancer screen.  It may be argued that 
the disutility of a false positive cancer screen often pertains to the patient (except in 
pediatric patients) whereas most of the emotional trauma of a false positive newborn 
screen is experienced by the infant’s family. 
5.10  SIGNIFICANCE OF THIS STUDY  
Since the expansion of its screening panel in 2007, this is the first study to 
estimate the cost-effectiveness of the newborn screening program in Texas.   Further 
expansions of the program are also imminent.  Results of the present study capture a 
variety of aspects related to newborn screening in Texas.  Cost estimates for laboratory 
activities (screening test) and case management activities (follow-up and treatment of 
positive cases) are included in this study.  The study methodology provides a compilation 
of disease prognosis and outcomes data (based on severity) obtained from a number of 
recent studies.  Study results may further substantiate the policy decision of expanding 
newborn screening in Texas.  Estimates of long-term costs may be useful in future plans 
regarding patient care.   So far, most of the focus of newborn screening in general is to 
provide short term diagnosis and care.  This study also highlights some of the existing 
gaps in the clinical, economic, and quality of life data related to newborn screening.  An 
increased awareness of these gaps in knowledge may stimulate additional research in 
these areas.   
5.11  FUTURE RESEARCH 
Newborn screening is an extremely diverse research area with implications in 
clinical research, health technology assessment, outcomes research, health policy, ethics 
and law.  Findings of the current study help in answering some of the questions related to 
the economic viability of the decision to expand newborn screening panel in Texas with 
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possible applications for the rest of the country as well.  At the same time, it also points 
to some major gaps in this important field of research.  Lack of good quality studies in 
health related quality of life in pediatric patients diagnosed with metabolic disorders is a 
case in point.  Economic impact of upcoming newborn screening expansions, their policy 
implications, and program evaluation of the current newborn screening program are all 



































































































































































































































































































Appendix B National Newborn Screening Status Report 
                                                      
Updated 05/04/09   
                                                                                                              
                                                                                                 
The U.S. National Screening Status Report lists the status of newborn screening in the United States.  
 
Dot "" indicates that screening for the condition is universally required by Law or Rule and fully implemented 
A = universally offered but not yet required, B = offered to select populations, or by request, C = testing required but not yet implemented 
D = likely to be detected (and reported) as a by-product of MRM screening (MS/MS) targeted by Law or Rule 
 
STATE 
Core1 Conditions Additional Conditions Included in  
Screening Panel (universally required  
unless otherwise indicated) 
Hearing Endocrine Hemoglobin Other 
HEAR CH CAH Hb S/S Hb S/A Hb S/C BIO GALT CF 
Alabama           
Alaska           
Arizona A          
Arkansas           
California B         HHH; PRO; EMA   
Colorado           
Connecticut         B  HHH; HIV 2 ; NKH 
D.C.          G6PD  
Delaware           
Florida           
Georgia A          
Hawaii           
Idaho A          
Illinois          NKH, 5-OXO, HIV 2 
Indiana           
Iowa           
Kansas           
Kentucky A          
Louisiana           
Maine A         HHH; CPS (D) 
Maryland          EMA 
Massachusetts          TOXO;  HHH, SCID (A);  CPS (D) 
Michigan          
Minnesota           
Mississippi          5-OXO; CPS; HHH  
Missouri           
Montana           
Nebraska A         5-OXO; HHH; NKH (A) 
Nevada A          
New Hampshire A         TOXO  
New Jersey           
New Mexico           
New York          HIV; HHH; Krabbe Disease 
North Carolina           
North Dakota A         HHH; NKH 
Ohio           
Oklahoma       C    
Oregon A          
Pennsylvania       C  C 5-OXO; CPS; G6PD; HHH; NKH  (B)  
Rhode Island           
South Carolina           
South Dakota A         5-OXO; EMA; HHH; NKH  
Tennessee          HHH; NKH  
Texas B        C  
Utah           
Vermont           
Virginia           
Washington A          
West Virginia           
Wisconsin A         SCID 
Wyoming           
1Terminology consistent with ACMG report - Newborn Screening: Towards a Uniform Screening Panel and System. Genet Med. 2006; 8(5) Suppl: S12-S252 
                            2Newborn screened for HIV only if mother was not screened during pregnancy 
 
Additional Conditions/Abbreviations and Names 
 
BIO Biotinidase CF Cystic fibrosis GALT Transferase deficient galactosemia (Classical) HB S/C Sickle – C disease HEAR Hearing screening 
CAH Congenital adrenal hyperplasia CH Congenital hypothyroidism HB S/S Sickle cell anemia HB S/A S-βeta thalassemia    
Other Disorders  
148 
 
5-OXO 5-oxoprolinuria (pyroglutamic aciduria) G6PD Glucose 6 phosphate dehydrogenase NKH Nonketotic hyperglycinemia 
CPS Carbamoylphosphate synthetase HHH Hyperammonemia/ornithinemia/ citrullinemia (Ornithine transporter defect) PRO Prolinemia 
EMA Ethylmalonic encephalopathy HIV Human immunodeficiency virus TOXO Toxoplasmosis 
 
  
         National Newborn Screening Status Report                 
                        Page 2  -  Updated 05/04/09 
 
Dot "" indicates that screening for the condition is universally required by Law or Rule and fully implemented 
A = universally offered but not yet required, B = offered to select populations, or by request, C = testing required but not yet implemented 
D = likely to be detected (and reported) as a by-product of MRM screening (MS/MS) targeted by Law or Rule 
 
STATE 
Core1 Conditions - Metabolic 














































































Alabama                     
Alaska                     
Arizona                     
Arkansas                     
California                     
Colorado                     
Connecticut                     
D. of Columbia                     
Delaware                     
Florida                    D 
Georgia                     
Hawaii                     
Idaho                     
Illinois                     
Indiana                     
Iowa                      
Kansas                     
Kentucky                     
Louisiana                     
Maine                     
Maryland                     
Massachusetts    D     D     D       
Michigan                     
Minnesota                     
Mississippi                     
Missouri                     
Montana                     
Nebraska                     
Nevada                     
New Hampshire                     
New Jersey                     
New Mexico                     
New York                     
North Carolina                     
North Dakota                     
Ohio                     
Oklahoma                     
Oregon D   D      D D   D       
Pennsylvania C C C C C C C C C C C C C C C C C   C 
Rhode Island                     
South Carolina                     
South Dakota                     
Tennessee                     
Texas                     
Utah                     
Vermont                     
Virginia                     
Washington         D            
West Virginia                     Wisconsin                     
Wyoming                     
1Terminology consistent with ACMG report - Newborn Screening: Towards a Uniform Screening Panel and System. Genet Med. 2006; 8(5) Suppl: S12-S252 
 
Deficiency/Disorder Abbreviations and Names (optional nomenclature) 
 




(Carnitine transport defect) CoA dehydrogenase hyperphenylalaninemia 
ASA Argininosuccinate aciduria GA-1 Glutaric acidemia type 1 MCAD Medium-chain acyl-CoA dehydrogenase PROP 
Propionic acidemia (Propionyl-
CoA carboxylase) 
BKT Beta ketothiolase  (mitochondrial acetoacetyl-CoA thiolase ; short-chain ketoacyl thiolase; T2) HCY 
Homocystinuria (cystathionine 
beta synthase) MCD 
Multiple carboxylase 
(Holocarboxylase synthetase ) TFP Trifunctional protein deficiency 
CBL A,B Methylmalonic acidemia  (Vitamin B12 Disorders) HMG 
3-Hydroxy 3 - methylglutaric 
aciduria (3-Hydroxy  3-
methylglutaryl-CoA lyase ) 
MSUD 
Maple syrup urine disease 
(branched-chain ketoacid 
dehydrogenase ) 
TYR-1 Tyrosinemia Type 1 
CIT I Citrullinemia type I  (Argininosuccinate synthetase) IVA 
Isovaleric acidemia (Isovaleryl-
CoA dehydrogenase ) MUT 
Methylmalonic Acidemia  
(methylmalonyl-CoA mutase) VLCAD 
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                                           Dot "" indicates that screening for the condition is universally required by Law or Rule and fully implemented 
                    A = universally offered but not yet required, B = offered to select populations, or by request, C = testing required but not yet implemented 
D = likely to be detected (and reported) as a by-product of MRM screening (MS/MS) targeted by Law or Rule 
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Alabama                D D        D 
Alaska                B B      B B  
Arizona D D D  D    D  D D      D D  D D   D 
Arkansas                          
California                          
Colorado                          
Connecticut                          
D. of Columbia                A A         
Delaware      D   D  D     D D         
Florida                          
Georgia  D    D  D  D   D D A        B B  
Hawaii                B B      B B  
Idaho                B B      B B  
Illinois  D  D  D   D       D D D        
Indiana                          
Iowa                           
Kansas                          
Kentucky A A A  A    A A A A A A A D D A  A A A    
Louisiana                          
Maine D D        D D  D       D  D    
Maryland                B B         
Massachusetts D D A A D D A D D D D  D A  D D A D D D D D D  
Michigan                        
Minnesota                          
Mississippi    A  A   A       A A     A    
Missouri                          
Montana D  D D D D D D D D D D D D  D D D  D D D    
Nebraska A  A  A   A  A  A A A A   A  A A     
Nevada                B B      B B A 
New Hampshire D D        D D D    D D D  D      
New Jersey                          
New Mexico A D A  A   A D D A A D D D B B A A A A D B B  
New York                          
North Carolina                          
North Dakota                          
Ohio                          
Oklahoma      D                     
Oregon  D       D D   D D D B B     D B B  
Pennsylvania B B B B B  B B  B B B B B B B B B  B B B    
Rhode Island  D                        
South Carolina                          
South Dakota                          
Tennessee      D                    
Texas D D D  D    D D D D    D D D  D D D    
Utah      D     D   D            
Vermont D D D  D     D D    D     D D D    
Virginia D D D D D D D D D D D D D  D D D D  D D D D D  
Washington D  D  D D   D D D D    D D  D D      
West Virginia D D D D D D D D D D D D D D D D D D  D D D    
Wisconsin                          




1Terminology consistent with ACMG report - Newborn Screening: Towards a Uniform Screening Panel and System. Genet Med. 2006; 8(5) Suppl: S12-S252 
 
 
Deficiency/Disorder Abbreviations and Names (optional nomenclature) 
 
2M3HBA 2-Methyl-3-hydroxy butyric aciduria CACT Carnitine acylcarnitine translocase GA-II 
Glutaric acidemia  
Type II MAL 
Malonic acidemia 
(Malonyl-CoA decarboxylase)  
2MBG 2-Methylbutyryl-CoA dehydrogenase   
CBL-C,D 
   
Methylmalonic acidemia  
(Cbl C,D)   GALE Galactose epimerase MCKAT 
Medium-chain ketoacyl-CoA 
thiolase 
3MGA 3-Methylglutaconic aciduria CIT-II Citrullinemia type II GALK Galactokinase  MET Hypermethioninemia 
ARG Argininemia (Arginase deficiency) CPT-Ia Carnitine palmitoyltransferase I H-PHE Benign hyperphenylalaninemia SCAD 
Short-chain acyl-CoA 
dehydrogenase 
BIOPT-BS Defects of biopterin cofactor  biosynthesis    CPT-II Carnitine palmitoyltransferase II IBG Isobutyryl-CoA dehydrogenase TYR-II Tyrosinemia type II 
BIOPT-
REG 
Defects of biopterin 
cofactor regeneration   De-Red Dienoyl-CoA reductase   M/SCHAD 
Medium/Short chain L-3-hydroxy 
acyl-CoA dehydrogenase TYR-III Tyrosinemia type III  
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Appendix C  Fee Schedule by State  
State 
Trends in Newborn Screening Fees Per Infant 
1996 1997 1998 1999 2000 2002 2004 
Alabama NA $24.00  $24.00  $24.00  $24.00  $34.00  $139.33  
Alaska  $24.00  $24.00  $24.00  $24.00  $24.00  $24.00  $55.00  
Arizona  $20.00  $20.00  $20.00  $20.00  $20.00  $20.00  $20.00  
Arkansas $14.83  $14.83  $14.83  $14.83  $14.83  $14.83  $14.83  
California $42.00  $42.00  $42.00  $42.00  $42.00  $60.00  $60.00  
Colorado  $33.50  $33.50  $33.50  $33.50  $33.50  $43.37  $53.25  
Connecticut $18.00  $18.00  $18.00  $18.00  $18.00  $28.00  $28.00  
Delaware $40.69  $40.69  $40.69  $40.69  $40.69  $40.69  $64.00  
District of 
Columbia 
No fee No fee No fee No fee No fee No fee No fee 
Florida $20.00  $20.00  $20.00  $20.00  $20.00  $20.00  $15.00  
Georgia No fee No fee No fee No fee No fee No fee No fee 
Hawaii No fee $4.00  $27.00  $27.00  $27.00  $27.00  $47.00  
Idaho No fee No fee No fee No fee No fee $18.00  $23.00  
Illinois $25.00  $25.00  $32.00  $32.00  $32.00  $32.00  $47.00  
Indiana  $22.10  $22.10  $22.10  $22.10  $28.50  $39.50  $39.50  
Iowa  $28.00  $30.00  $30.00  $30.00  $33.00  $46.00  $56.00  
Kansas No fee No fee No fee No fee No fee No fee No fee 
Kentucky NA $14.50  $14.50  $14.50  $14.50  $14.50  $14.50  
Louisiana $12.00  $12.00  $12.00  $18.00  $18.00  $18.00  $40.00  
Maine $18.00  $18.00  $18.00  $26.75  $26.75  $33.00  $44.00  
Maryland $15.75  $15.75  $15.75  $15.75  $15.75  $30.00  $42.00  
Massachusetts  $42.00  $42.00  $42.00  $49.55  $49.55  $49.55  $54.75  
Michigan  $28.02  $28.02  $28.58  $29.38  $39.00  $42.61  $54.84  
Minnesota $13.00  $13.00  $21.00  $21.00  $21.00  $21.00  $61.00  
Mississippi $20.00  $20.00  $20.00  $20.00  $35.00  $25.00  $70.00  
Missouri $25.00  $15.00  $15.00  $13.00  $13.00  $25.00  $25.00  
Montana $15.00  $15.00  $18.50  $35.50  $36.92  $36.92  $39.34  
Nebraska NA No fee $54.60  $54.60  $54.60  $54.60  $64.00  
Nevada NA $30.00  $30.00  $30.00  $30.00  $30.00  $30.75  
New 
Hampshire 
NA $12.50  $12.50  $12.50  $18.00  $18.00  $18.00  
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New Jersey $27.00  $27.00  $27.00  $34.00  $34.00  $34.00  $71.00  
New Mexico  $20.00  $20.00  $20.00  $20.00  $20.00  $32.00  $32.00  
New York No fee No fee No fee No fee No fee No fee No fee 
North Carolina No fee No fee No fee No fee No fee $10.00  $10.00  
North Dakota $15.00  $15.00  $15.00  $16.00  $17.00  $18.00  $36.00  
Ohio $27.00  $27.00  $27.00  $27.50  $27.00  $33.75  $33.75  
Oklahoma $10.50  $10.50  $10.50  $10.50  $10.50  $10.50  $75.59  
Oregon  $28.00  $28.00  $32.00  $32.00  $32.00  $54.00  $54.00  
Pennsylvania $18.50  $12.00  $18.50  No fee No fee No fee No fee 
Rhode Island $59.00  $59.00  $59.00  $55.00  $59.00  $59.00  $59.00  
South Carolina $21.00  $21.00  $21.00  $21.00  $21.00  $21.00  $42.00  
South Dakota No fee No fee No fee No fee No fee No fee $16.20  
Tennessee $10.00  $10.00  $10.00  $10.00  $17.50  $17.50  $47.50  
Texas No fee No fee $13.75  $13.75  $13.75  $19.50  $19.50  
Utah  $21.00  $21.00  $27.50  $27.50  $27.00  $31.00  $31.00  
Vermont  $21.00  $21.00  $21.00  $27.00  $27.00  $27.00  $33.30  
Virginia $16.00  $16.00  $16.00  $16.00  $16.00  $27.00  $32.00  
Washington  $39.90  $33.80  $35.75  $35.75  $39.25  $40.40  $60.90  
West Virginia No fee No fee $15.85  $12.64  $20.46  No fee No fee 
Wisconsin $43.25  $44.00  $45.50  $55.50  $55.50  $59.50  $65.50  
Wyoming $12.25  $12.25  No fee No fee No fee No fee $45.00  
Source: Johnson K, Lloyd-Puryear MA, Mann MY, Ramos LR, Therrell BL. Financing 
state newborn screening programs: sources and uses of funds. Pediatrics. May 
2006;117(5 Pt 2):S270-279. 
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Appendix D  Example Newborn Screening 




Appendix E  Abnormal Screen Result 
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Appendix F  Fact Sheet Galactosemia (GALT) 
What is GALT? 
GALT is a rare, inherited problem. It is caused 
when the body can’t break down galactose. 
Galactose is a sugar found in milk and milk 
products. 
What Causes GALT? 
Breast milk and most infant formulas have a 
sugar called lactose. The body breaks lactose 
down into sugars called glucose and galactose. 
Galactose must be broken down more before 
the body can use it for energy. An enzyme called 
galactose-1-phosphate uridyl transferase helps 
do this. Enzymes help start chemical reactions in 
the body. Most people with GALT don’t have this 
special enzyme. This causes galactose to build up 
in the body. 
What Symptoms or Problems Occur 
with GALT? 
[Symptoms are something out of the ordinary 
that a parent notices.] 
High levels of galactose poison the body and 
cause these serious problems: 
 swollen liver 
 kidney failure 
 stunted growth and mental retardation 
 cataracts in the eyes 
Children and young adults treated for GALT may 




 clumsiness with hands 
 bleeding in the gel-like part of the eye 
 tremors (shaking) 
 stunted growth 







What is the Treatment for GALT? 
Special Diet – The treatment for GALT is to limit 
galactose and lactose from the diet for life. All 
milk and all foods that have milk in them must 
not be used at all. This includes any kind of 
milk, such as cow’s milk, goat’s milk, and human 
breast milk. Your child should also not eat dairy 
products like butter, cheese, and yogurt. Other 
foods with small amounts of milk products must 
also not be eaten. These include foods with whey, 
casein, and curds. 
Things to Remember 
Children with GALT should be in the care of a 
doctor who specializes in the treatment of GALT. 
You will also have a dietitian who will teach you 
about special diets for your child. Dietitians know 
what are the right foods to eat. 
Read labels carefully when you shop for your 
child’s food. Many prepared foods have hidden 
ingredients that contain galactose. 
Many medicines contain fillers that include 
galactose. It is important to ask the doctor 
and pharmacist about this for any medicines  
prescribed for your child. 
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Appendix G  Act Sheet: Galactosemia 
Appendix G Act Sheet: Galactosemia 
Disclaimer: This information is adapted from American College of Medical Genetics 
website ACT sheets. http://www.acmg.net/resources/policies/ACT/condition-analyte-
links.htm 10/06 
Absent/Reduced Galactose-1-phosphate Uridyltransferase (GALT) 
Classical Galactosemia 
 
Differential Diagnosis: Galactosemia (galactose-1-phosphate uridyltransferase 
deficiency); GALT 
heterozygotes; GALT variants; artifactual reductions due to enzyme inactivation by high 
temperature 
and/or humidity. 
Condition Description: In galactosemia, GALT deficiency results in accumulation of 
galactose-1-phosphate 
(Gal-1-P), and galactose, causing multiorgan disease. 
 
Medical Emergency: Take the Following Immediate Actions 
 Contact family to inform them of the newborn screening result, ascertain clinical 
status, arrange immediate clinical evaluation, stop breast or cow’s milk, and 
initiate non-lactose feeding (powder-based soy formula). 
 Consult with metabolic specialist; refer if considered appropriate. 
 Evaluate the infant (jaundice, poor feeding, vomiting, lethargy, bulging fontanel, 
and bleeding), and arrange diagnostic testing as directed by metabolic specialist. 
 Initiate emergency treatment as recommended by metabolic specialist. If baby is 
sick, admit to hospital. 
 Repeat newborn screen if second screen has not yet been done. 
 Educate family about importance of diet change. 
 Report findings to newborn screening program. 
 
Confirmation of Diagnosis: 
Quantification of erythrocyte galactose-1-phosphate (gal-1-P) and GALT. 
Classical galactosemia shows <1% GALT activity and markedly increased gal-1-P. 
Transfusions in infant can invalidate the results of erythrocyte enzyme assays. Enzyme 
variants may be distinguished by GALT electrophoresis or mutation analysis. 
Clinical Considerations: Classical galactosemia presents in the first few days of life and 
may be fatal without treatment. Signs include poor feeding, vomiting, jaundice and, 
sometimes, lethargy and/or bleeding. Neonatal E. coli sepsis can occur and is often 




New England Metabolic Consortium 
http://www.childrenshospital.org/newenglandconsortium/NBS/gal/gal_protocol.htm 
 
Gene Tests/Gene Clinics  
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Appendix H   
TABLE  H.1 ASA AND CIT: PROBABILITY OF DEATH WITH NO SCREEN 
Cycle Low Base High 
0 0.24 0.3 0.36 
1 0.16 0.2 0.24 
2 0.08 0.1 0.12 
3 0.08 0.1 0.12 
4 0.04 0.05 0.06 
5 0.016 0.02 0.024 
6 0.008 0.01 0.012 
7 0.008 0.01 0.012 
8 0.004 0.005 0.006 
9 0.004 0.005 0.006 
10 0.004 0.005 0.006 
11 - 75 0 0 0 
76 0 0 0 
 0.644 0.805 0.966 
 
TABLE H.2 ASA AND CIT : PROBABILITY OF DEATH WITH SCREEN 
Cycle Low Base High 
0 0.16 0.2 0.24 
1 0.08 0.1 0.12 
2 0.08 0.1 0.12 
3 0.08 0.1 0.12 
4 0.04 0.05 0.06 
5 0.016 0.02 0.024 
6 0.008 0.01 0.012 
7 0.008 0.01 0.012 
8 0.004 0.005 0.006 
9 0.004 0.005 0.006 
10 0.004 0.005 0.006 
11 - 75 0 0 0 
76 0 0 0 
 0.484 0.605 0.726 
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TABLE H.3 ASA AND CIT: PROBABILITY OF MENTAL RETARDATION 
WITH NO SCREEN 
Cycle Low Base High 
0 0.032 0.04 0.048 
1 0.032 0.04 0.048 
2 0.032 0.04 0.048 
3 0.032 0.04 0.048 
4 0.032 0.04 0.048 
5 – 75  0 0 0 
76 0 0 0 
 0.16 0.2 0.24 
 
TABLE H.4 ASA AND CIT: PROBABILITY OF MENTAL RETARDATION 
WITH SCREEN 
Cycle Low Base High 
0 0.032 0.04 0.048 
1 0.032 0.04 0.048 
2 0.032 0.04 0.048 
3 0.032 0.04 0.048 
4 0.032 0.04 0.048 
5-75 0 0 0 
76 0 0 0 
 0.16 0.2 0.24 
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TABLE H.5 HCY: PROBABILITY OF DEATH WITH NO SCREENING 
Cycle Low Base High 
0 0.009 0.03 0.051 
1 0.009 0.03 0.051 
2 0.006 0.02 0.034 
3 0.006 0.02 0.034 
4 0.003 0.01 0.017 
5 0.0021 0.007 0.0119 
6 0.0021 0.007 0.0119 
7 0.0015 0.005 0.0085 
8 0.0015 0.005 0.0085 
9 0.0015 0.005 0.0085 
10 0.00003 0.0001 0.00017 
11 0.00003 0.0001 0.00017 
12 0.00003 0.0001 0.00017 
13 0.00003 0.0001 0.00017 
14 0.00003 0.0001 0.00017 
15 0.00003 0.0001 0.00017 
16 0.00003 0.0001 0.00017 
17 0.00003 0.0001 0.00017 
18 0.00003 0.0001 0.00017 
19 -75 0 0 0 
76 0 0 0 
  0.04197 0.1399 0.23783 
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TABLE H.6 HCY: PROBABILITY OF DEATH WITH  SCREENING 
Cycle Low Base High 
0 0 0.02 0.034 
1 0 0.02 0.034 
2 0 0.01 0.027 
3 0 0.01 0.027 
4 0 0.01 0.027 
5 0 0.007 0.0119 
6 0 0.007 0.0119 
7 0 0.005 0.0085 
8 0 0.005 0.0085 
9 0 0.005 0.0085 
10 0 0.0001 0.00017 
11 0 0.0001 0.00017 
12 0 0.0001 0.00017 
13 0 0.0001 0.00017 
14 0 0.0001 0.00017 
15 0 0.0001 0.00017 
16 0 0.0001 0.00017 
17 0 0.0001 0.00017 
18 0 0.0001 0.00017 
19-75 0 0 0 
76 0 0 0 




TABLE H.7 HCY: PROBABILITY OF MENTAL RETARDATION WITH NO 
SCREENING 
Cycle Low Base High 
0 0.32 0.36 0.4 
1 0.2 0.225 0.25 
2 0.08 0.09 0.1 
3 0.04 0.045 0.05 
4 0.032 0.036 0.04 
5 0.0064 0.0072 0.008 
6 0.0064 0.0072 0.008 
7 0.0064 0.0072 0.008 
8 0.0064 0.0072 0.008 
9 0.0064 0.0072 0.008 
10 0.0064 0.0072 0.008 
11 0.0064 0.0072 0.008 
12 0.0064 0.0072 0.008 
13 0.0064 0.0072 0.008 
14 0.0064 0.0072 0.008 
15 - 75 0.000918 0.001033 0.001148 
76 0.000918 0.001033 0.001148 
  0.792941 0.892058 0.991176 
 
TABLE H.8 HCY: PROBABILITY OF MENTAL RETARDATION WITH  
SCREENING 
Cycle low base high 
0 0 0.04 0.09 
1 0 0.02 0.04 
2 0 0.01 0.02 
3 0 0.01 0.02 
4 0 0.005 0.001 
5 0 0.001 0.002 
6 0 0.001 0.002 
7 0 0.001 0.002 
8 0 0.001 0.002 
9 0 0.001 0.002 
10 - 75 0 0 0 
76 0 0 0 
  0 0.09 0.181 
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TABLE H.9 HCY: PROBABILITY OF LENS DISLOCATION WITH NO 
SCREENING 
Cycle Low Base High 
0 0.005714 0.007143 0.008572 
1 0.005714 0.007143 0.008572 
2 0.005714 0.007143 0.008572 
3 0.005714 0.007143 0.008572 
4 0.005714 0.007143 0.008572 
5 0.005714 0.007143 0.008572 
6 0.005714 0.007143 0.008572 
7 0.04 0.05 0.06 
8 0.056 0.07 0.084 
9 0.16 0.2 0.24 
10 0.08 0.1 0.12 
11 0.064 0.08 0.096 
12 0.04 0.05 0.06 
13 0.024 0.03 0.036 
14 0.016 0.02 0.024 
15 - 75 0.00264 0.0033 0.00396 
76 0.00016 0.0002 0.00024 
  0.567121 0.708901 0.850681 
 
TABLE H.10 HCY: PROBABILITY OF LENS DISLOCATION WITH 
SCREENING 
Cycle low base high 
0 0 0 0 
1 0 0 0 
2 0 0 0 
3 0 0 0 
4 0 0 0 
5 0 0 0 
6 0 0 0 
7 0 0 0 
8 0 0.005 0.01 
9 0 0.01 0.02 
10 0 0.02 0.04 
11 0 0.01 0.02 
12 0 0.005 0.01 
13 - 75 0 0 0 
76 0 0 0 
  0 0.05 0.1 
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TABLE H.11 HCY: PROBABILITY OF SPINAL OSTEOPOROSIS WITH NO 
SCREENING 
Cycle low base high 
0 0 0 0 
1 0 0 0 
2 0 0 0 
3 0 0 0 
4 0 0 0 
5 0 0 0 
6 0.0007 0.001 0.0013 
7 0.0007 0.001 0.0013 
8 0.0007 0.001 0.0013 
9 0.0007 0.001 0.0013 
10 0.0007 0.001 0.0013 
11 0.0035 0.005 0.0065 
12 0.0035 0.005 0.0065 
13 0.035 0.05 0.065 
14 0.035 0.05 0.065 
15 0.12 0.18 0.24 
16 0.035 0.05 0.065 
17 0.035 0.05 0.065 
18 0.021 0.03 0.039 
19 0.014 0.02 0.026 
20 0.007 0.01 0.013 
21 0.0035 0.005 0.0065 
22 0.0035 0.005 0.0065 
23 0.0035 0.005 0.0065 
24 0.0035 0.005 0.0065 
25 0.0035 0.005 0.0065 
26 0.0035 0.005 0.0065 
27 0.0035 0.005 0.0065 
28 0.0035 0.005 0.0065 
29 0.0035 0.005 0.0065 
30 - 75 0.00014 0.0002 0.00026 
76 0.00014 0.0002 0.00026 
  0.35058 0.5094 0.66822 
 
 165 
TABLE H.12 HCY: PROBABILITY OF SPINAL OSTEOPOROSIS WITH  
SCREENING 
Cycle low base high 
0 0 0 0 
1 0 0 0 
2 0 0 0 
3 0 0 0 
4 0 0 0 
5 0 0 0 
6 0 0 0 
7 0 0 0 
8 0 0 0 
9 0 0 0 
10 0 0 0 
11 0 0 0 
12 0 0 0 
13 0 0.005 0.01 
14 0 0.01 0.02 
15 0 0.02 0.04 
16 0 0.01 0.02 
17 0 0.005 0.01 
18 - 75 0 0 0 
76 0 0 0 
  0 0.05 0.1 
 
TABLE H.13 MSUD: PROBABILITY OF DEATH WITH NO SCREEN 
Cycle low estimate high 
0 0.68 0.75 0.82 
1 0.12 0.15 0.18 
2 - 75 0 0 0 
76 0 0 0 
  0.8 0.9 1 
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TABLE H.14 MSUD: PROBABILITY OF DEATH WITH SCREEN 
Cycle low estimate high 
0 0.0075 0.01 0.0125 
1 0.0075 0.01 0.0125 
2 0.0075 0.01 0.0125 
3 0.0075 0.01 0.0125 
4 0.0075 0.01 0.0125 
5 0.00075 0.001 0.00125 
6 0.00075 0.001 0.00125 
7 0.00075 0.001 0.00125 
8 0.00075 0.001 0.00125 
9 0.00075 0.001 0.00125 
10 0.00075 0.001 0.00125 
11 0.00075 0.001 0.00125 
12 0.00075 0.001 0.00125 
13 0.00075 0.001 0.00125 
15 0.00075 0.001 0.00125 
17 - 75 0 0 0 
76 0 0 0 
  0.045 0.06 0.075 
 
TABLE H.15 MSUD: PROBABILITY OF NEUROLOGICAL DAMAGE WITH 
NO SCREEN 
Cycle Value 1 Value 2 Value 3 
0 0.015 0.02 0.025 
1 0.015 0.02 0.025 
2 0.015 0.02 0.025 
3 0.015 0.02 0.025 
4 0.0075 0.01 0.0125 
5 0.00075 0.001 0.00125 
6 0.00075 0.001 0.00125 
7 0.00075 0.001 0.00125 
8 0.00075 0.001 0.00125 
9 0.00075 0.001 0.00125 
10 0.00075 0.001 0.00125 
11 0.00075 0.001 0.00125 
12 0.00075 0.001 0.00125 
13 0.00075 0.001 0.00125 
15 0.00075 0.001 0.00125 
17 - 75 0 0 0 
76 0 0 0 
  0.075 0.1 0.125 
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TABLE H.16 MSUD: PROBABILITY OF NEUROLOGICAL DAMAGE WITH 
SCREEN 
Cycle low estimate high 
0 0.015 0.02 0.025 
1 0.015 0.02 0.025 
2 0.015 0.02 0.025 
3 0.015 0.02 0.025 
4 0.0075 0.01 0.0125 
5 0.00075 0.001 0.00125 
6 0.00075 0.001 0.00125 
7 0.00075 0.001 0.00125 
8 0.00075 0.001 0.00125 
9 0.00075 0.001 0.00125 
10 0.00075 0.001 0.00125 
11 0.00075 0.001 0.00125 
12 0.00075 0.001 0.00125 
13 0.00075 0.001 0.00125 
15 0.00075 0.001 0.00125 
17 - 75 0 0 0 
76 0 0 0 
  0.075 0.1 0.125 
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TABLE H.17 MSUD: PROBABILITY OF DEVELOPMENTAL DELAY WITH 
NO SCREEN 
Cycle low estimate high 
0 0.0075 0.01 0.0125 
1 0.0075 0.01 0.0125 
2 0.0075 0.01 0.0125 
3 0.0075 0.01 0.0125 
4 0.0075 0.01 0.0125 
5 0.00075 0.001 0.00125 
6 0.00075 0.001 0.00125 
7 0.00075 0.001 0.00125 
8 0.00075 0.001 0.00125 
9 0.00075 0.001 0.00125 
10 0.00075 0.001 0.00125 
11 0.00075 0.001 0.00125 
12 0.00075 0.001 0.00125 
13 0.00075 0.001 0.00125 
15 0.00075 0.001 0.00125 
17 - 75 0 0 0 
76 0 0 0 
  0.045 0.06 0.075 
 
TABLE H.18 MSUD: PROBABILITY OF DEVELOPMENTAL DELAY WITH  
SCREEN 
Cycle low estimate high 
0 0.009 0.01 0.011 
1 0.00375 0.005 0.00625 
2 0.00075 0.001 0.00125 
3 0.00075 0.001 0.00125 
4 0.00075 0.001 0.00125 
5 0.00075 0.001 0.00125 
6 0.00075 0.001 0.00125 
7 0.00075 0.001 0.00125 
8 0.00075 0.001 0.00125 
9 - 75 0 0 0 
76 0 0 0 
  0.018 0.022 0.026 
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TABLE H.19 TYROSINEMIA: PROBABILITY OF CLINICAL DIAGNOSIS 
WITH NO SCREEN 
Cycle Low base High 
0 0.25 0.35 0.45 
1 0.15 0.25 0.35 
2 0.1 0.2 0.05 
3 0.1 0.1 0.05 
4 0.1 0.05 0.05 
5 0.1 0.02 0.05 
6 0.1 0.01 0 
7 0.1 0.01 0 
8 0 0.01 0 
9 - 75 0 0 0 
76 0 0 0 
  1 1 1 
 
TABLE H.20 TYROSINEMIA: PROBABILITY OF LIVER DAMAGE WITH NO 
SCREEN 
Cycle Low Base High 
0 0.05 0.06 0.07 
1 0.03 0.04 0.05 
2 0.01 0.02 0.03 
3 - 15 0 0 0 
76 0 0 0 
  0.09 0.12 0.15 
 
TABLE H.21 MCADD: PROBABILITY OF DEATH WITH NO SCREEN 
Cycle low base high 
0 0.108 0.12 0.132 
1 0.036 0.04 0.044 
2 0.009 0.01 0.011 
3 0.009 0.01 0.011 
4 0.009 0.01 0.011 
5 0.009 0.01 0.011 
6 0.009 0.01 0.011 
7 0.009 0.01 0.011 
8 0.009 0.01 0.011 
9 0.009 0.01 0.011 
10 0.009 0.01 0.011 
11 - 75 0 0 0 
76 0 0 0 




TABLE H.22 MCADDD: PROBABILITY OF DEATH WITH SCREEN 
Cycle low base high 
0 0.009 0.01 0.011 
1 0.009 0.01 0.011 
2 0.009 0.01 0.011 
3 0.0045 0.005 0.0055 
4 0.0009 0.001 0.0011 
5 0.0009 0.001 0.0011 
6 0.0009 0.001 0.0011 
7 0.0009 0.001 0.0011 
8 0.00009 0.0001 0.00011 
9 0.00009 0.0001 0.00011 
10 0.00009 0.0001 0.00011 
11 0.00009 0.0001 0.00011 
12 0.00009 0.0001 0.00011 
13 0.00009 0.0001 0.00011 
14 0.00009 0.0001 0.00011 
15 0.00009 0.0001 0.00011 
16 0.00009 0.0001 0.00011 
17 0.00009 0.0001 0.00011 
18 0.00009 0.0001 0.00011 
19 0.00009 0.0001 0.00011 
20 0.00009 0.0001 0.00011 
21 0.00009 0.0001 0.00011 
22 0.00009 0.0001 0.00011 
23 0.00009 0.0001 0.00011 
24 0.00009 0.0001 0.00011 
25 0.00009 0.0001 0.00011 
26 0.00009 0.0001 0.00011 
27 0.00009 0.0001 0.00011 
28 0.00009 0.0001 0.00011 
29 0.00009 0.0001 0.00011 
30 0.00009 0.0001 0.00011 
31 0.00009 0.0001 0.00011 
32 0.00009 0.0001 0.00011 
33 - 75 0 0 0 
76 0 0 0 
  0.03735 0.0415 0.04565 
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TABLE H.23 GA I: PROBABILITY OF DEATH WITH NO SCREEN 
Cycle Low Estimate High 
0 0.018 0.02 0.022 
1 0.018 0.02 0.022 
2 0.018 0.02 0.022 
3 0.018 0.02 0.022 
4 0.018 0.02 0.022 
5 0.018 0.02 0.022 
6 0.018 0.02 0.022 
7 0.018 0.02 0.022 
8 0.018 0.02 0.022 
9 0.018 0.02 0.022 
10 0.018 0.02 0.022 
11 0.018 0.02 0.022 
12 0.018 0.02 0.022 
13 0.018 0.02 0.022 
14 0.018 0.02 0.022 
15 0.018 0.02 0.022 
16 - 75 0 0 0 
76 0 0 0 
  0.288 0.32 0.352 
 
TABLE H.24 GA I: PROBABILITY OF DEATH WITH SCREEN 
Cycle Low Estimate High 
0 0.009 0.01 0.011 
1 0.009 0.01 0.011 
2 0.009 0.01 0.011 
3 0.009 0.01 0.011 
4 0.00225 0.0025 0.00275 
5 0.00225 0.0025 0.00275 
6 0.00225 0.0025 0.00275 
7 0.00225 0.0025 0.00275 
8 0.00009 0.0001 0.00011 
9 0.00009 0.0001 0.00011 
10 0.00009 0.0001 0.00011 
11 0.00009 0.0001 0.00011 
12 0.00009 0.0001 0.00011 
13 0.00009 0.0001 0.00011 
14 0.00009 0.0001 0.00011 
15 0.00009 0.0001 0.00011 
16 - 75 0 0 0 
76 0 0 0 
  0.04572 0.0508 0.05588 
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TABLE H.25 GA I: PROBABILITY OF NEUROLOGICAL DAMAGE WITH NO 
SCREEN 
Cycle low estimate high 
0 0.27 0.35 0.385 
1 0.198 0.27 0.297 
2 0.108 0.12 0.132 
3 0.054 0.06 0.066 
4 0.036 0.04 0.044 
5 0.027 0.03 0.033 
6 0.009 0.01 0.011 
7 0.009 0.01 0.011 
8 0.0045 0.005 0.0055 
9 0.0045 0.005 0.0055 
10 0.0045 0.005 0.0055 
11 0.00009 0.0001 0.00011 
12 0.00009 0.0001 0.00011 
13 0.00009 0.0001 0.00011 
14 0.00009 0.0001 0.00011 
15 0.00009 0.0001 0.00011 
16 - 75 0 0 0 
76 0 0 0 
  0.72495 0.9055 0.99605 
 
TABLE H.26 GA I: PROBABILITY OF NEUROLOGICAL DAMAGE  WITH 
SCREEN 
Cycle low estimate high 
0 0.045 0.05 0.055 
1 0.045 0.05 0.055 
2 0.045 0.05 0.055 
3 0.045 0.05 0.055 
4 0.045 0.05 0.055 
5 0.036 0.04 0.044 
6 0.018 0.02 0.022 
7 0.018 0.02 0.022 
8 0.009 0.01 0.011 
9 0.0045 0.005 0.0055 
10 0.0045 0.005 0.0055 
11 0.00009 0.0001 0.00011 
12 0.00009 0.0001 0.00011 
13 0.00009 0.0001 0.00011 
14 0.00009 0.0001 0.00011 
15 0.00009 0.0001 0.00011 
16 - 75 0 0 0 
76 0 0 0 
  0.31545 0.3505 0.38555 
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TABLE H.27 COAD: PROBABILITY OF DEATH WITH NO SCREEN 
Cycle Low Estimate High 
0 0.18 0.2 0.22 
1 0.18 0.2 0.22 
2 0.045 0.05 0.055 
3 0.009 0.01 0.011 
4 0.009 0.01 0.011 
5 0.009 0.01 0.011 
6 0.009 0.01 0.011 
7 0.0045 0.005 0.0055 
8 0.0045 0.005 0.0055 
9 0.0045 0.005 0.0055 
10 - 75 0 0 0 
76 0 0 0 
  0.4545 0.505 0.5555 
 
TABLE H.28 COAD: PROBABILITY OF DEATH WITH SCREEN 
Cycle Low Estimate High 
0 0.036 0.04 0.044 
1 0.018 0.02 0.022 
2 0.009 0.01 0.011 
3 0.009 0.01 0.011 
4 0.0045 0.005 0.0055 
5 0.0045 0.005 0.0055 
6 0.0045 0.005 0.0055 
7 0.0045 0.005 0.0055 
8 0.0045 0.005 0.0055 
9 0.0045 0.005 0.0055 
10 - 75 0 0 0 
76 0 0 0 
  0.099 0.11 0.121 
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TABLE H.29 COAD: PROBABILITY OF NEUROLOGICAL DAMAGE  WITH 
NO SCREEN 
Cycle Low Estimate High 
0 0.0081 0.009 0.0099 
1 0.0081 0.009 0.0099 
2 0.0405 0.045 0.0495 
3 0.0405 0.045 0.0495 
4 0.0405 0.045 0.0495 
5 0.0405 0.045 0.0495 
6 0.0405 0.045 0.0495 
7 0.0405 0.045 0.0495 
8 0.0405 0.045 0.0495 
9 0.0405 0.045 0.0495 
10 0.0639 0.071 0.0781 
11 0.0639 0.071 0.0781 
12 0.0639 0.071 0.0781 
13 0.0639 0.071 0.0781 
14 0.0639 0.071 0.0781 
15 - 75 0 0 0 
76 0 0 0 
  0.6597 0.733 0.8063 
 
TABLE H.30 COAD: PROBABILITY OF NEUROLOGICAL DAMAGE  WITH 
SCREEN 
Cycle Low Estimate High 
0 0.0054 0.006 0.0066 
1 0.0054 0.006 0.0066 
2 0.0108 0.012 0.0132 
3 0.0108 0.012 0.0132 
4 0.0108 0.012 0.0132 
5 0.0135 0.015 0.0165 
6 0.0135 0.015 0.0165 
7 0.0135 0.015 0.0165 
8 0.0135 0.015 0.0165 
9 0.0135 0.015 0.0165 
10 0.027 0.03 0.033 
11 0.027 0.03 0.033 
12 0.027 0.03 0.033 
13 0.027 0.03 0.033 
14 0.027 0.03 0.033 
15 - 75 0 0 0 
76 0 0 0 
  0.2457 0.273 0.3003 
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TABLE H.31 COAD: PROBABILITY OF CHRONIC RENAL FAILURE  WITH  
NO SCREEN 
Cycle Low Estimate High 
0 0.0009 0.001 0.0011 
1 0.0009 0.001 0.0011 
2 0.0009 0.001 0.0011 
3 0.0009 0.001 0.0011 
4 0.0018 0.002 0.0022 
5 0.0018 0.002 0.0022 
6 0.054 0.06 0.066 
7 0.054 0.06 0.066 
8 0.054 0.06 0.066 
9 0.054 0.06 0.066 
10 0.054 0.06 0.066 
11 0.045 0.05 0.055 
12 0.045 0.05 0.055 
13 0.0018 0.002 0.0022 
14 0.0018 0.002 0.0022 
15 - 75 0 0 0 
76 0 0 0 
  0.3708 0.412 0.4532 
 
TABLE H.32 COAD: PROBABILITY OF CHRONIC RENAL FAILURE WITH 
SCREEN 
Cycle Low Estimate High 
0 0 0 0 
1 0 0 0 
2 0 0 0 
3 0 0 0 
4 0 0 0 
5 0 0 0 
6 0.009 0.01 0.011 
7 0.009 0.01 0.011 
8 0.009 0.01 0.011 
9 0.009 0.01 0.011 
10 0.009 0.01 0.011 
11 - 75 0 0 0 
76 0 0 0 
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